

=> d his

(FILE 'HOME' ENTERED AT 13:38:29 ON 07 JUL 2008)

FILE 'REGISTRY' ENTERED AT 13:38:47 ON 07 JUL 2008

L1 STRUCTURE UPLOADED

L2 26 S L1

L3 515 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:41:00 ON 07 JUL 2008

L4 231 S L3

L5 55 S L4 AND PY<2003

=> s l4 and py<2005

25089442 PY<2005

L6 100 L4 AND PY<2005

=> d l-100 bib abs hitstr

LE ANSWER 1 OF 100 CAPLIS: OMPYX002 2006 ACS on STN (Continued)

AK 2006 E02000 CAPLIS

IN 145 17900

TI Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism

IN Harsco, Jlepa, Anantarama, Mohan Mark, Weist, Denise Kramer, Bhawale, Parthiban, Ishwara, Nodden, Sybil, Pataki, Ahmed, Johnson, Bruce Fletcher, Williams, Amy Casey

IN General Electric Company, USA

50 U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S. Ser. No. 2002,311,000A (USC100)

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

IN 145 17900

LE ANSWER 1 OF 100 CAPLIS: OMPYX002 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

PAGE 2-C

PAGE 1-C

PAGE 2-A

PAGE 2-B




LE ANKER 1 OF 100 CAPLIC OMFKIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 3-B



PAGE 3-C



OR 2

CIN 14477-72-6
CIN 12 75 02

IT 1077028-69-RDP, resin bound 1077028-70-130, resin bound

1077028-16-131, resin bound 1077028-72-07

1077028-82-10 1077028-84-77 1077028-88-19

1077028-84-131, resin bound 1077028-91-27

1077028-99-40

E.C. ECT (Ectactase), STN (Synthetic preparation), PSP (Preparation), NACT

(Synthetic or reagent)

CIN 14477-72-6, resin bound 1077028-70-130, resin bound

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC


CIN 1077028-69-0 CAPLIC

CIN 1077028-69-0 CAPLIC


CIN 1077028-69-0 CAPLIC

LE ANKER 1 OF 100 CAPLIC OMFKIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B




PAGE 2-C




LE ANKER 1 OF 100 CAPLIC OMFKIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A




• K

LE ANWER 1 OF 100 CAPLIS OFFRIGHT 2006 ACS on STM (Continued)

PAGE 2-B




IN 1027028-10-1 CAPLIS
CN INDEX NAME NOT YET ASSIGNED
Absolute stereochemistry
Double bond geometry unknown




PAGE 1-A

PAGE 1-B




LE ANWER 1 OF 100 CAPLIS OFFRIGHT 2006 ACS on STM (Continued)


PAGE 1-B



PAGE 1-C




PAGE 2-A



LE ANWER 1 OF 100 CAPLIS OFFRIGHT 2006 ACS on STM (Continued)

PAGE 2-A




● K

IN 1027028-10-7 CAPLIS
CN INDEX NAME NOT YET ASSIGNED

CN 1
CN 1027028-10-6
CIP C139 H144 N151 K159 ST


Absolute stereochemistry
Double bond geometry unknown

PAGE 1-A



LE ANWER 1 OF 100 CAPLIS OFFRIGHT 2006 ACS on STM (Continued)

PAGE 2-B



CN 2
CN 14477-72-6
CIP C2 P3 M2




IN 1027028-10-0 CAPLIS
CN INDEX NAME NOT YET ASSIGNED

CN 1
CN 1027028-10-9
CIP C131 H144 N151 K159 ST


Absolute stereochemistry
Double bond geometry unknown

LE ANDER 1 OF 100 CAPLIC OMFYKIGT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




LE ANDER 1 OF 100 CAPLIC OMFYKIGT 2006 ACS on STN (Continued)


PAGE 1-C



PAGE 2-A



PAGE 2-B



CM 2

CIN 14473-72-6

CIP C2 P3 M1



LE ANDER 1 OF 100 CAPLIC OMFYKIGT 2006 ACS on STN (Continued)

IN 1027029-84-5 CAPLIC

IN 1027029-84-5 CAPLIC

CM 1


CIN 1027029-84-5

CIP C12 P12 N22 M18 M18


Absolute stereochemistry

Double bond geometry unknown

PAGE 2-A




PAGE 2-B




LE ANDER 1 OF 100 CAPLIC OMFYKIGT 2006 ACS on STN (Continued)


PAGE 1-C



PAGE 2-A



PAGE 2-B



CM 2

CIN 14473-72-6

CIP C2 P3 M1



IN 1027029-84-7 CAPLIC


LE NUMBER 1 OF 100 CAPLIC OMPYRIGHT 2006 ACS on STM (Continued)
CN INDEX NAME NOT YET ASSIGNED

CM 1


CBN 1027005-55-6
CMF C142 H222 N2S 045 06

Absolute stereochemistry
Double bond geometry unknown

PAGE 1-A



PAGE 1-B



LE NUMBER 1 OF 100 CAPLIC OMPYRIGHT 2006 ACS on STM (Continued)
CM 2

CBN 14417-72-6
CMF C2 F0 00




BN 1027005-55-6 CAPLIC
CN INDEX NAME NOT YET ASSIGNED

CM 1

CBN 1027005-57-0
CMF C142 H222 N2S 045 06


Absolute stereochemistry
Double bond geometry unknown

PAGE 1-A




LE NUMBER 1 OF 100 CAPLIC OMPYRIGHT 2006 ACS on STM (Continued)


PAGE 1-C



PAGE 2-A




PAGE 2-B




LE NUMBER 1 OF 100 CAPLIC OMPYRIGHT 2006 ACS on STM (Continued)

PAGE 1-B




PAGE 1-C




LE ANKER 1 OF 100 CAPLIS OMPYKIGET 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B




CN 2


CN 14417-72-6
CN 12 75 62BN 100508-96-1 CAPLIS
CN INDEX NAME NOT ASSIGNEDAbsolute stereochemistry
Double bond geometry unknown

LE ANKER 1 OF 100 CAPLIS OMPYKIGET 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



LE ANKER 1 OF 100 CAPLIS OMPYKIGET 2006 ACS on STN (Continued)


PAGE 2-A



PAGE 2-B



PAGE 3-A




●● R


BN 100508-97-2 CAPLIS
CN INDEX NAME NOT ASSIGNEDAbsolute stereochemistry
Double bond geometry unknown

LE ANKER 1 OF 100 CAPLIS OMPYKIGET 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



LE ANKER 1 OF 100 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)
 CN 1627058-99-5
 CIP C145: 1019 AC6 014 57
 PAGE 1-C

LE ANKER 1 OF 100 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)
 CN 1627058-99-5
 CIP C145: 1019 AC6 014 57
 Absolute stereochemistry
 Double bond geometry unknown

PAGE 1-A




● S


PAGE 2-B

— OCH₃

BN 1627058-99-4 CAPLIS
 CN INDEX NAME NOT TEST ASSIGNED
 CM 1





PAGE 1-B



LE ANKER 1 OF 100 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)
 CN 1627058-99-4 CAPLIS
 CIP C145: 1019 AC6 014 57
 PAGE 1-C

LE ANKER 1 OF 100 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)



PAGE 2-B

— OCH₃

CM 2
 CN 16417-72-6
 CIP C2 P5 62

LE ANDREW 3 OF 100 CAPLICE COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



LE ANDREW 4 OF 100 CAPLICE COPYRIGHT 2006 ACS on STN

AN 2006/052926 CAPLICE

IN 145,26216

T1 Aromatic tertiary nitrogen mustards for single-pot attachment of a label

to nucleic acid

IN Stattin, Paul M.; Wolfr, Ron A.; Hagstrom, James E.; Becker, Vladimir G.

PR Wyne Bio Corporation, USA

SD U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 415,943;

COWV US3309

BT Patent

LA English

PAN CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006/018021	A1	2006/06/24	US 2006/415061	2006/06/01
US 73,3789	B2	2006/06/06		
US 6302302	B1	2000/07/17	US 1997/067685	1997/10/02
US 2000/012527	A1	2000/05/03	US 2000/067794	2000/05/25
US 6336465	B2	2000/07/15		
US 2000/012064	A1	2000/06/08	US 2000/282222	2000/03/31
US 2004/020404	A1	2004/08/21	US 2000/415942	2000/04/15
US 1991/468027	F	1991/08/19		
US 1991/951585	A1	1991/12/02		
US 2001/767794	A2	2001/05/23		
US 2000/354222	A2	2000/06/01		
US 2000/415961	A2	2000/04/15		

QC BAFAT 145,26216

AS Canada and methods are provided for a single-pot covalent attachment of a label to nucleic acids comprising forming a covalently attachable labeling reagent for alkylating the mol., then combining the covalently attachable labeling reagent with a mixture containing the mol., under conditions wherein the labeling reagent has reactivity with the mol. thereby forming a covalent bond


IT 731856-14 CAPLICE 60-7
 RE: AGO Analytical reagent used; ACT (Reagent); ANCT (Analytical study);
 NACT (Reagent or reagent); USES (Uses)

aromatic tertiary nitrogen mustards for single-pot attachment of label to nucleic acids

IN 731856-14 CAPLICE

ON 2R Indolium, 2-[3-{1-[4-{[4-(2-chloroethyl)amino]amino]phenyl}-6,3,5-triazol-10,13,16,22,25,28,32-octam-7,10,16,26,30-tetraazabenzotriaz-1-yl]-3,4-dihydro-5,3-dimethyl-2-sulfo-2H-indol-2-ylidene]-1,3-pentadecan-1-yl]-4-methyl-5,3-dimethyl-2-sulfo-, inner salt (CA 3062, NAME)

PAGE 1-A



LE ANDREW 4 OF 100 CAPLICE COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



LE ANDREW 4 OF 100 CAPLICE COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

-CH2Cl

IT 611199-30-SP, Label-11-C65


RE: AGO Analytical reagent used; ACT (Reagent); SPN (Synthetic preparation); ANCT (Analytical study); PMP (Preparation); ACT (Reagent or reagent); USES (Uses)

aromatic tertiary nitrogen mustards for single-pot attachment of label to nucleic acids

IN 611199-30-SP CAPLICE

ON 2R Indolium, 2-[3-{1-[6-{[3-{[4-{(2-chloroethyl)amino]amino]phenyl}-4-methylamino]propyl]amino]amino]amino]-4-methyl-5,3-dimethyl-2-sulfo-2H-indol-2-ylidene]-1,3-pentadecan-1-yl]-4-methyl-5,3-dimethyl-2-sulfo-, bis(inner salt) (CA 3062, NAME)


PAGE 1-A



PAGE 1-B

IN 000073-60-7 CAPLICE
 ON 2R Indolium, 2-[3-{1-[6-{[3-{[4-{(2-chloroethyl)amino]amino]phenyl}-4-methylamino]propyl]amino]amino]amino]-4-methyl-5,3-dimethyl-2-sulfo-2H-indol-2-ylidene]-1,3-pentadecan-1-yl]-4-methyl-5,3-dimethyl-2-sulfo-, inner salt (CA 3062, NAME)

PAGE 1-A



RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



LE ANKER 6 OF 100 CAPSULE OMPYK002 2006 ACS on STN (Continued)
 P-2-ethyl-6-pentafluorophenyl-1,2,3,4-tetrahydro-2,4-dioxo-1-
 pyridinyl-2-propyl[amino-2-methyl-ethoxy[ethoxy]benzyl]amino[eth-
 yl]amino-4-oxoheptyl-1,3,5-dihydro-2,3-dimethyl-5-methyl-20-methyl-2-ylidene-1,3-
 pentadiene-1-yl]-1-ethyl-3,5-dimethyl-5-sulfur, inner salt, compd with
 N,N-dibutyl-1-butanamine (BCT) (CA INDEX NAME)

Cl 1


CM 699430-54-7

CP 029 014 303 026 78 30


Absolute stereochemistry

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



Cl 2

CM 102-82-9

CP 112 213 N

LE ANKER 6 OF 100 CAPSULE OMPYK002 2006 ACS on STN (Continued)

n-Bu

n-Bu-N-Bu

IT 699430-54-7

RE ACT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT
 (Reaction or reagent)


Curiosities/nucleotides conjugated to labels via cleavable linkages

and their use in nucleic acid sequencing

IN 699430-54-7 (CAPSULE)

ON 3H-Indolizine, 2-[5'-[1-[6-[1-[5'-[2'-acetyl-5'-[2'-
 (carboxyphenyl)ethyl]ethyl]benzo[1,3,4-d]oxadiazol-5-yl]amino-4-oxoheptyl]-1,3-
 dihydro-3,5-dimethyl-5-sulfo-20-methyl-2-ylidene-1,3-pentadiene-1-yl]-1-ethyl-3,5-
 dimethyl-5-sulfur, inner salt (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



NO

CH-O-CH2-CH2-O-CH2-OCH3

LE ANKER 7 OF 100 CAPSULE OMPYK002 2006 ACS on STN (Continued)
 IN 0000-2506410 CAPSULE
 IN 141,11926
 IT SSCP method for quantitative determination of spinal muscular
 atrophy associated gene (SMN)
 IN Novelli, Giuseppe, Jairo, Franceschi, Demetrio, Salina, Brancati,
 Francesco, Tacconelli, Alessandra, Dellapioola, Deino
 PA Centro Nazionale delle Ricerche, Italy
 SO Ital., IT (2)
 COORD TACONELLI
 JP Patent
 LA Italian

PATENT NO.	KIND	DATE	APPLICATION NO	DATE
P1 IT 1518102	B1	20000827	IT 2000-M23041	20000609 (---)
PRAT IT 2000-M23041	A1	20000819		
AB IT 2000-M23041		20000819		

AB Spinal muscular atrophy (SMA) is an autosomal recessive genetic disease
 occurring at a rate of 1:10,000. One of every 40-60 individuals is a
 carrier. The SMA locus has been mapped to chromosome 5q13.2-13.3. SMA is
 caused by a deletion of the SMN gene, which is present in two copies (SMN1
 and SMN2). These genes differ by only 6 nucleotides. SMA results from
 alterations in heterozygosity of only the SMN1 gene. Described is a
 sensitive and specific method based on SSCP (Single-strand conformation
 polymorphism) for quantification of the SMN1 gene relative to a control
 gene (G8).

IT SSCP-97-1, Cyt-MCP
 RE ASU (Analytical role, unclassified); ANST (Analytical study)
 primer containing SSCP method for quant. determination of spinal muscular
 atrophy-associated gene (SMN)


IN 001171-17-1 CAPSULE
 IN 3H-Indolizine, 2-[5'-[1-[6-[1-[5'-[2'-acetyl-5'-[2'-
 (carboxyphenyl)ethyl]ethyl]benzo[1,3,4-d]oxadiazol-5-yl]amino-4-oxoheptyl]-1,3-
 dihydro-3,5-dimethyl-5-sulfo-20-methyl-2-ylidene-1,3-pentadiene-1-yl]-1-ethyl-3,5-
 dimethyl-5-sulfur, inner salt (CA INDEX NAME)

Absolute stereochemistry

Double bond geometry unknown.


PAGE 1-A

NO




LE ANKER 7 OF 100 CAPSULE OMPYK002 2006 ACS on STN (Continued)

PAGE 1-B



LE ANDER 11 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B

LE ANDER 11 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-B

RE CNT 06 THERE ARE 06 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE PNOAT

PAGE 2-A

LE ANDER 12 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS


IN 0004-3040005 CAPLUS

IN 0004-3040005 CAPLUS


IN 0004-3040005 CAPLUS

LE ANDER 12 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C

Absolute stereochemistry
Double bond geometry unknown

L6 ANSWER 16 OF CAPLUS COPYRIGHT 2009 ACS ON STM
 AN 2004-033159 CAPLUS
 IN 141-152769
 TI Alkylating compounds and processes for single-pot attachment of a label to
 an acid
 DA Stead, Paul M.; Wolff, Jon A.; Hagston, James E.; Bodker, Vladimir G
 IN USA
 SO U S Pat. App. Publ., 41 pp.
 OO OREGON TEXCO
 DT Patent
 LA English
 PAN CNT 6
 PATENT NO. KIND. DATE APPLICATION NO. DATE

PT	US 2006/011064	A1	2004/0496	US 2000-35822	2005/0131
	WO 2006/011064	A2	2004/0496	US 2000-35822	2005/0098
	US 2006/070902	A2	2004/1014		
	EP 1997-0410	A1			
	JP 157815	DE, DK, ES, FR, GB, CH, CY, CZ, SE, SK, SI, TR, UA, NL, NO, PL, PT, RU, UA, UK, JP, KR, HK, TW, IL, IN, AU, BR, CA, CL, CO, CR, CU, EE, EG, FI, GR, HU, IE, IT, JP, KR, LI, LU, MA, MX, NZ, PE, PG, PH, PK, PR, PT, RO, RU, SG, SI, SK, TH, TR, UA, US, VN, ZA, ZW	DE, DK, ES, FR, GB, CH, CY, CZ, SE, SK, SI, TR, UA, NL, NO, PL, PT, RU, UA, UK, JP, KR, HK, TW, IL, IN, AU, BR, CA, CL, CO, CR, CU, EE, EG, FI, GR, HU, IE, IT, JP, KR, LI, LU, MA, MX, NZ, PE, PG, PH, PK, PR, PT, RO, RU, SG, SI, SK, TH, TR, UA, US, VN, ZA, ZW		
PRAL	US 2006/039527	A1	2004/0354	US 2000-41503	2006/0060
	US 2006/039527	A2	2004/0354		
	US 1997-067029	P	1997/0619		
	US 2001-067046	A1	1997/1200		
	US 2001-167194	A1	2001/0912		
	US 2006-035222	A1	2005/0431		
	US 2006-106227	A1	2005/0640		
	US 2006-106227	A2	2005/0640		
	US 2006-106227	A3	2005/0640		
	US 2006-106227	A4	2005/0640		

[illegible]

IT 731858-31-4 731858-33-9 731858-33-0
731858-54-1 731858-57-4
RL AGO (Analytical reagent use); ANST (Analytical study); USES (Uses)
(alkylating compds. and processes for single-pot attachment of label to
nucleic acid)



RN 731868-31-4 CAPLUS

TABLE ANSWER 16 OF 100 CAPLUS, COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-10


—CHO.

731855-53-0 CAPLUS
3H-Indolium, 2-[3-[1-[6-[3-[1-[4-[[2-(2-chloroethyl)methylamino]phenyl]methyl-
amino]propyl]amino]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-
2-ylidene]-1,3-pentadiene-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, bis(inner
salt) (anion) (CA INDEX NAME)



RW 791859-54-1 CAPLUS
 CN 3H-Indolium, 2-[3-{1-[4-{[2-(chloroethyl)methylamino]phenyl}-6,3,3,5-tetrazolo-10,15,16,19,22,25,28,33-octaoxa-7,30,36,60-tetraazabenzotetracont-1-yl]-1,3-dithio-3,3-dimethyl-8-sulfo-2H-indol-2-ylidene)-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-8-sulfo-, inner salt (CA INDEX NAME)


PAGE 1-A



LE ANSWER 16 OF 100 CAPLIS COPYRIGHT 2000 ACS ON STN (Continued)

CN 3H-Inchium, 2-[5-[1-[6-[1-[3-[1-[3-[1-[4-[2-chloroethyl)methylamino]phenyl]methylamino]propyl]dimethylamino]propyl]amino]-6-oxyhexyl]-1,3-dihydro-3,5-dimethyl-5-sulfo-2H-indol-2-yl]idene]-1,3-pentadien-1-yl]-1-ethyl-5,5-dimethyl-5-sulfo-, bis(inner salt) (CAS INDEX NAME)

2428 1-4




PAGE 3-2

$$-\text{CH}_2-\text{CH}_2\text{Cl}$$


731858-52-9 CAPLUS
 2H-Indolizin, 2-[3-[1-[6-[[3-[[[4-(2-chloroethyl)methylamino]phenyl]methyl]amino]propyl]amino]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1-propen-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, bis(inner salt), ion(2-) (CA INDEX NAME)

PAGE 1-1


C=Cc1ccc(cc1)N(CCCNC(CCC)CCC(=O)N(CCC)CCC(=O)Nc2ccccc2)c3ccccc3

16 ANSWER 16 OF 100 CAPLUS, COPYRIGHT 2009 ACS on STM (Continued)

PAGE 5-3




PAGE 1-C




RN 731858-57-4 CAPLUS
 CN 3H-Indolium, 2-[2-[[1-[6-[[[(8S)-6-amino-6-[[[(8S)-6-amino-6-[[[4-[[[2-(chloroethyl)methylamino]phenyl]ethyl]amino]-6-oxoethyl]amino]-6-oxoethyl]amino]-1,3-dihydro-6,3-dimethyl-6-sulfo-2H-indol-2-ylidene]-1-propen-1-yl]]-1-ethyl-6,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

Absolute stereochemistry:
Double bond geometry unknown




L6 ANSWER 16 OF 109 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
PAGE 1-B



```

17 61199-00-0P
   RE: ARG (Analytical reagent use); SPN (Synthetic preparation); AN7
   (Analytical compounds); PREP (Preparation); UDS (Use)
   Satisfying compounds and processes for singlet attachment of label to
   nucleic acid
18 61199-00-0 CASLUS
   28-Indol-3-yl-[1-(2-[1-(2-[3-(2-[4-(2-[3-chloroethyl]ethylamino)phenyl]
   ethylamino)propyl]dimethylammonio)propyl]amino)-6-naphthyl]-3,3-dihydro-
   2H-indol-2-ylidene-2H-indol-1-ylpropan-1-yl]-1-ethyl-3,3-
   dimethyl-8-methyl-3-oxo-1,3-dioxane-5-carboxamide
   (CAS INDEX NAME)

```



PAGE 1-A

PMR 1-B



L6 ANSWER 17 OF 100 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)

RE CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANSWER 17 OF 100 CAPLUS COPYRIGHT 2008 ACS on STD
AN 2004 E29854 CAPLUS

AD Springer, Joerg Pomeroy, Daniel P. Whyake, Masato Demnet, Loesle.

CS Forschungszentrum Molekulare Katalyse Lehrstuhl für Anorganische Chemie,
Technische Universität München, Garching, 85748, Germany
30 Angewandte Chemie, International Edition (2004), 43 (29),
5095-5099


0009-2781/95/0005-0000\$10.00
© 1995 Wiley-VCH Verlag GmbH & Co., KGaA

AB High-throughput screening of libraries of potential inhibitors is possible by using an enzyme microarray method that combines low nanomole consumption

with accurate 3' end speed. Information about enzyme inhibition can be obtained "on-chip" by the addition of a fluorescently tagged affinity label to a microarray of functional enzymes.


of cytosine protease activation)
 767290-21-7 CAPLUS
 L-Lysineamide, N-[[[(2S,3S)-3-(ethoxycarbonyloxy)tranyllcarbonyll-L-leucyl-L-tyrosyl-6-aminohexanoyll-MG-[6-[2-[3-[3-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-5-sulfo-2H-indolol-1-carbonyll-oxo, inner salt (OCE) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown



PAGE 1-A

PAGE 3-7



L6 ANSWER 18 OF 100 CAPLUS COPYRIGHT 2008 ACS on STD
AN 2004:008026 CAPLUS


70 4001:00300 Carlos
 71 141:150181
 72 Single-step attachment of a label to siRNA
 73 Skattum, Paul M.; Bodker, Vladimir G.; Hagstrom, James E.; Wolff, Jon A
 74 USA
 75 U.S. Pat. Appl. Publ., 17 pp.
 76 C000N: USKLC9
 77 Patent
 78 English

[illegible]

ABSTRACT 141:135181
 AB Compa. and methods are provided for a single-pot covalent attachment of a label to an siRNA, comprising forming a covalently attachable labeling reagent for alkylating the mol. Then, combining the covalently attachable labeling reagent with a mixture containing the mol., under conditions wherein the labeling reagent has reactivity with the mol. thereby forming a covalent bond.

IT 727379-96-ED, LabelIT-Cy 5, siRNA conjugate 727380-23-ED
siRNA conjugate
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(single-step attachment of label to siRNA)

727379-16-6. 0 PLUS
 CN 3H-Indolino, 2-[6-{1-[5-{3-[[3-[[4-(2-chloroethyl)methylamino]phenyl]methylamino]propyl]dimethylammonio]propyl]amino}-5-oxopentyl]-1, 2-dichloro-3, 3-dimethyl-6-methyl-2H-indol-2-ylidene]-1, 3-pentadien-1-yl]-1-ethyl-3, 3-dichloro-1-methyl-6-methyl-2H-1, 2, 4-triazole-5-carboxamide. (CN, VPPHY, TMS)



PAGE 3-1

LE ANKER 20 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 1-A

LE ANKER 21 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for molecular diffusion as revealed by

A0 Murase, Koton; Fujiwara, Takahito; Umemura, Yumiko; Suzuki, Kenichi;

Tate, Ryota; Iwashita, Hiroaki; Saitoh, Shinsuke; Aoyama, Hiroyuki;

Ritsche, Ren; Kume, Akihito

CS Super Resolution Observer Project, Institute Research for Advanced

Technology Organization (SRATO-20057), Japan Science and Technology

Agency, Nagoya, Japan

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments, delineated by transmembrane proteins anchored

to the membrane skeleton (anchored protein model), would provide

the membrane with fundamental functions because they would affect the

movement of practically all molecules incorporated in the cell membrane.

Understanding such basic compartmentalized structures of the cell membrane

is critical for further studies of a variety of membrane functions. Here,

using both high temporal-resolution single particle tracking and single

fluorescent mol. video analysis of an animal, phospholipid, we found

that plasma membrane compartments generally exist in various cell types,

including CN, HEPA-OMA, FRC, FRC, FRC, FRC, FRC, FRC, FRC, FRC, FRC,

cells. The compartment size varies from 50 to 200 nm, whereas the average hop

rate of DMF crossing the boundaries between two adjacent compartments

ranges between 1 and 11 ms. The probability of finding a compartment

barrier near DMF is already at the boundary is also cell-type dependent,

with an overall variation by a factor of approx. 2. These results strongly

indicate the necessity for the paradigm shift of the concept on the plasma

membrane: from the two-dimensional fluid continuum model to the

compartmentalized membrane model in which its constituent mol. undergo

hop diffusion over the compartments.

T1 754296-31-4

R: RU (Olefinol study, unclassified): FFP (Properties), BUC.

(Olefinol study)

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS

IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

AN 2004:151484 CAPLUS


IN 141:136249

T1 Ultrafine membrane compartments for mol. diffusion as revealed by

single mol. techniques

RE CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANKER 21 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 1-A

LE ANKER 22 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

A0 Geertz, Nathalie; Fick, Horst; Vogel, Horst; Johnson, Nils; Johnson, Kai

CS Institute of Chemical Sciences and Engineering, Ecole Polytechnique

Fédérale de Lausanne (EPFL), Lausanne, CH-1015, Switz.

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse


Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

RE CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PAGE 1-B

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS

IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse

Compounds

AN 2004:151484 CAPLUS


IN 141:136249

T1 Specific Labeling of Cell Surface Proteins with Chemically Diverse


Compounds

L6 ANSWER 23 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PM10 2-4



PMSE 3-9



PAGE 2-C



RN 701277-09-0 CAPLUS
 CN L-Histidinamide, L-cysteinylglycyl-N6-[6-[2-[3-[1,3,5,8,5D-6-(1-ethyl)-1,3-dihydro-4,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-pentadienyl]-2,3-dimethyl-5-sulfo-3H-indol-3-oxohexyl]-L-valylglycyl-4-(4-(1-aminooethyl))


L6 ANSWER 23 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-D


[illegible]

Absolute stereochemistry
Double bond geometry as shown

PAGE 1-A




PAGE 1-B




L6 ANSWER 25 OF 100 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
2-methoxy-5-nitrophenoxylbutanoyl[2-(2-aminoethoxy)ethoxy]acetyl[2-(2-
aminoethoxy)ethoxy]acetyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-
histidyl-, inner salt (XCI) (CA INDEX NAME)

Absolute stereochemistry
Double bond geometry as shown


PAGE 3-A



PAGE 1-2




PAGE 1-C




L6 ANSWER 23 OF 100 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

PAGE 1-C



PAGE 1-3




700277-11-4 CAPLUS
L-lysineamide, L-cysteine[tyr]glycyl-66-[6-[3-[(1E,3E,6E)-6-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-6-sulfo-2H-indol-1(3H)-oxyethyl]-L-tyrosylglycyl[2-(2-aminoethoxy)ethyl]thiazyl[2-(2-aminoethyl)thio]ethyl-L-aspartyl-L-tyrosyl-L-lysyl-L-aspartyl-L-aspartyl-L-cysteine-L-tyrosyl-L-lysylglycyl, inner salt (9CI) CA INDEX

Absolute stereochemistry.
Double bond geometry as shown.

U6 ANSWER 23 OF 109 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-C



IN 704890-56-6 CAPLUS
CN Glycylamide, L- α -tryptophylglycyl-N6-[6-{2-[(1E,3E,5E)-5-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-5-sulfo-3H-indol-10-yl-1-oxypropyl]-L-lysylglycyl-4-{4-[1-aminooethyl]-3-methoxy-6-nitrophenyl}butan-2-yl-2-[(2-aminooethyl)ethoxy]acetyl-N6-[5-{2*S*,4*S*,6*R*]-hexahydro-2-oxo-1*H*-thiazol-3,4-*d*-yl]-1-oxypropyl]-L-lysyl-, inner salt (XCl) (CA 70664 NABE)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




L6 ANSWER 23 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




PAGE 1-C




16 ANSWER 25 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-3



PAGE 3-C

[illegible]

Absolute stereochemistry.
Double bond geometry as shown

L6 ANSWER 23 OF 100 CAPLUS COPYRIGHT 2008 ACS on STM (Cost Issues)


PAGE 1-2




204894-04-2 CAPJUS
 Glycineamide, L-cysteineglycyl-L-N⁶-(2-[(1E,3E,5E)-5-(1-ethyl-1,3-dihydro-2H-1,4-benzodioxin-2-ylidene)-2-methylidene]-3-oxo-2-oxetan-1-yl)-3,4-dihydro-2H-1,4-benzodioxin-2-ylidene-L-lysyl-L-tyrosyl-L-4-[(1-aminophenyl)-2-methoxy-5-nitrophenyl]butanoyl[2-(2-aminophenyl)-2-oxoethyl]acetyl[2-(3-aminophenyl)ethoxy]acetyl-N⁶-(1E,3E,5E,6R)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazo[4,5-b]-1-ncopenityl-L-lysyl-, inner salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown

PAGE 1-A




PAGE 1-8






Absolute stereochemistry—
Double bond geometry as shown.

PAGE 1-A




Absolute stereochemistry.
Double bond geometry as shown.


PAGE 3-A




PAGE 1-B



PAGE 1-C

CCCC(=O)NCCOC(=O)CNC(=O)COCCOC(=O)CCC

PAGE 3-C




PAGE 1-7




Absolute stereochemistry.
Diphile bond geometry as shown.


PAGE 1-2



PAGE 1-5




PAGE 3-C




U6 ANSWER 27 OF 109 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A

[illegible]

CM 1


CSX 674799-48-5

CMF C129 H180 N21 009 S2


Absolute stereochemistry
Double bond geometry unknown

16 ANSWER 27 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-2



L6 ANSWER 27 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-C



16 ANSWER 27 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
disulfo-1H-benz[e]indole]-1-oxohexyl]-L-lysylglycyl-, inner salt,
acetate, sodium-potassium salt (KCl) (CA INDEX NAME)

disulfo-1H-benz[e]indoliz-1-onehexyl]-L-lysylalanyl-, inner salt, acetate, pentapotassium salt (9CI) (CA INDEX NAME)


Q1

CRM 674799-50-9


CMF C121 H154 N21 CG6 SE

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-8



PAGE 1-2




IN 674799-01-0 CAPLUG
CN L-⦿-Asparagine, N-[6-[2-[7-[1-[(3,5-dimethoxyphenyl)methyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3,5-heptatrienyl]-2,3-dimethyl-5-sulfo-3H-indol-1-yl]-2-propenyl]glycyl-L-prolyl-L-leucylglycyl-L-valyl-L-arginylglycyl-5S-[6-[2-[5-[3-ethyl-1,3-dihydro-1,1-dimethyl-4,8-disulfo-2H-benz[e]sulfon-2-ylidene)-3-pentadienyl]-1,1-dimethyl]-6,8-


disult

LE ANKER 27 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-B




CN 2


CN TI-50-1

LE ANKER 27 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



PAGE 2-B

~OEt



PAGE 3-A

LE ANKER 27 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN C2 ED 02




BN 674799-62-5 CAPLUS

L-Tyrosinamide, N-[6-[2-[5-(2-ethyl-1,5-dihydro-1,1-dimethyl-4,8-dithio-2H-benz[e]indol-2-ylidene)-1,3-pentadienyl]-1,1-dimethyl-4,8-dithio-2H-benz[e]indol-1-yl]methyl]acetyl-NM-[[[4-[2-[bis(carboxymethyl)amino]-2-carboxyl]amino]-5-[2-[bis(carboxymethyl)amino]thiomethyl]-1-tryptophanyl]ethyl]-[O,4-dihydro-5,5,6,6-tetraethyl-2H-1-benzopyran-7-yl]oxy]propanolammonium salt (K⁺), inner salt, tripotassium salt (K⁺) (CA INDEX NAME)


Absolute stereochemistry:
Double bond geometry unknown.

PAGE 1-A



LE ANKER 27 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 4-A



● K

PAGE 4-B

~OEt


BN 674799-62-5 CAPLUS

L-Tyrosinamide, N-[6-[2-[5-(2-ethyl-1,5-dihydro-1,1-dimethyl-4,8-dithio-2H-benz[e]indol-2-ylidene)-1,3-pentadienyl]-1,1-dimethyl-4,8-dithio-2H-benz[e]indol-1-yl]methyl]acetyl-NM-[[[4-[2-[bis(carboxymethyl)amino]-2-[2-[bis(carboxymethyl)amino]ethyl]-5-carboxymethyl]amino]propanolammonium salt (K⁺), inner salt, tripotassium salt (K⁺) (CA INDEX NAME)


Absolute stereochemistry:
Double bond geometry unknown.

LE ANKER 27 OF 100 CAPLIS COPYRIGHT 2009 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



LE ANKER 27 OF 100 CAPLIS COPYRIGHT 2009 ACS on STN (Continued)


PAGE 1-C



ON 1
 CN 674799-64-5
 CNF 0140-1039 NCE 044-57


Absolute stereochemistry:
 Double bond geometry unknown.

PAGE 1-A



LE ANKER 27 OF 100 CAPLIS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B



LE ANKER 27 OF 100 CAPLIS COPYRIGHT 2009 ACS on STN (Continued)
 RE CNF 71 THERE ARE 0 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


CN 2

CN 14417-72-4
 CNF 02-93-02




U6 ANSWER 28 OF 109 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-5




IT 666847-60-EP 666847-61-EP 666847-62-1P
666847-9C-EP 666848-08-4P
RL RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of modified nucleotides and their enzymic incorporation into
DNA)

IN 666847-60-5 CAPUS
 CN 3S-Indolium, 1-[6-[[2-[(2-carboxyethyl)dithio]ethyl]amino]-6-oxohexyl]-2-
 [(1E,3S)-3-(1-ethyl-1,5-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1-
 propen-1-yl]-5,3-dimethyl-5-sulfo-, inner salt [CA INDEX NAME]
 Double bond geometry as shown.

Double bond geometry as shown.


PAGE 1-A




L6 ANSWER 28 OF 100 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)
 ophexyl]-1,3-dihydro-5,3-dimethyl-6-sulfo-2H-indol-2-ylidene]-1-propen-1-
 yl]-1-methyl-3,3-dimethyl-6-sulfo-, inner salt (CA INDEX NAME)

Absolute stereochemistry
Double bond geometry as shown

PAGE 1-A



PAGE 1-5



IN 666847-96-6 CAPLUS
CN 32-Indolium, 2-[(1R,3R)-3-[1-[6-[2-[3-[3-[4-amino-7-[3-O-(acidomethyl)-2-deoxy-5-O-(hydroxy)(hydroxy phosphonyloxy)thiosthinyloxy]phosphinyl]-P-2'-thiothio-pentofuranosyl]-7H-purro[1,2-3,5-diaziridin-5-yl]-2-propen-1-yl]amino]-5-oxopropyl]ethyl]amino]-6-cyanoethyl]-3,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1-propen-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt [CA INDEX NAME]

Absolute stereochemistry:
Double bond geometry as shown


16 ANSWER 28 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B




Absolute stereochemistry:
Double bond geometry as shown

PAGE 3-8




PAGE 1-8




IN 666847-82-1 CAPUS
 CN 3H-Indolium, 2-[(1E,3E)-3-[1-{6-[[2-[[3-[[3-{2-amino-7-[3-0-(azidomethyl)-2-deoxy-5- β -[hydroxy][hydroxy]phosphonoxyl]phosphinyl]oxy]phosphoryl]- β -D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo-3H-pyrido[2,3-b]pyrimidin-5-yl]-2-propenyl-1-yl]amino]-3-oxopropyl]diethyl]amino]-6-

LE ANSWER 28 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-N



PAGE 1-5



IN 666948-06-4 CAPLUS
CN 3H-indol-5yl, 2-((3,3E)-3-[[6-[[[2-[[[3-[[3-[[2-deoxy-5-O-
[hydroxy[[hydroxy(phosphonoxy)phosphoryl]oxy]phosphoryl]-5-O-2-propen-1-yl]-
1-0-2-erythro-pentofuran-1-yl]-1,2,4,4-tetrahydro-2,4-dioxo-5-
pyrimidin]-2-2-propen-1-yl]amino)-3-oxocyclop[ditin]ethyl]amino]-6-
oxocyclo-1,3,3-dihydro-5,3-dimethyl-5-sulfo-2H-indol-2-ylidene-1-propen-1-
yl]-1-ethyl)-3,3-dimethyl-5-methyl-, inner salt, (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

16 ANDER 31 00 100 CAPLUS COPYRIGHT 2008 ACS on STM
 17 141-277487
 18 141-277487

19 Real-time Detection of Polymerase Activity During Supercritical Angle
 Fluorescence

20 Brink, Alexander; Nakatani, Thomas; Lath, Stephan; Seeger, Stefan
 21 Physikalisch-Chemisches Institut, Universität Zurich, Zurich, 8057,
 22 Switzerland

23 Journal of Fluorescence 18(6), 70-78
 24 ISSN 1051-0851, ISSN 1662-0069
 25 Elsevier Academic/Plenum Publishers

26 Zurich

27 We investigated the incorporation efficiencies of different fluorescently
 28 labeled dNTPs with polymerase by complementary strand synthesis. For
 29 this reason single stranded DNA was immobilized on a coverslip and the
 30 increase of fluorescence due to the synthesis of the corresponding strand
 31 with labeled dNTPs was detected with a supercritical angle fluorescence
 32 microscope in real-time. By comparison of the observed signal intensities it
 33 was possible to conclude that the system Cy5-dCTP-Klenow (exonuclease
 34 free) fragment gives the best incorporation yield of the investigated
 35 enzymes and dNTPs.

36 105141-71-1, Fluorescence, 949-677

37 38. 39. 40. Biological study, unclassified; 39.06. Biological study
 41 (real-time detection of polymerase activity using supercrit. angle
 42 fluorescence)

43 105141-71-1 CAPLUS


44 38-Indolium, 2-[6-[[1-[6-[[2-(4-amino-1-[2-deoxy-5-O-
 45 (D-riboxy[4,5-bisphosphonoxy]oxyphosphoryl]oxy]phosphoryl]-4-
 46 methoxyphenyl]-1,3-dihydro-2-imidazo[1,2-a]pyrimidin-1-yl]amino]-4-
 47 oxahexyl]-1,3-dihydro-3,5-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-
 48 pentadien-7-yl]-1-ethyl-3,5-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

49 Absolute stereochemistry

50 Double bond geometry unknown.

PAGE 1-A

100--



16 ANDER 32 00 100 CAPLUS COPYRIGHT 2008 ACS on STM
 17 2004-41139 CAPLUS

18 141-266221

19 Cysteine-binding fluorescent cyanine dyes for saturation labelling of
 20 proteins and application in 2D-gel electrophoresis

21 Williams, Karen; Stone, Timothy; Edwards, Adrian Christopher; Sweet,
 22 Alison Claire; Fowler, Susan Janet

23 Biocytin Biosciences UK Limited, UK

24 OCT 2nd, 1991, 58 pp

25 0020-717X(2001)

26 Patent

27 Zurich

28 105141-71-1

29 105141-71-1

30 105141-71-1

31 105141-71-1

32 105141-71-1

33 105141-71-1

34 105141-71-1

35 105141-71-1

36 105141-71-1

37 105141-71-1

38 105141-71-1

39 105141-71-1

40 105141-71-1

41 105141-71-1

42 105141-71-1

43 105141-71-1

44 105141-71-1

45 105141-71-1

46 105141-71-1

47 105141-71-1

48 105141-71-1

49 105141-71-1

50 105141-71-1

51 105141-71-1

52 105141-71-1

53 105141-71-1

54 105141-71-1

55 105141-71-1

56 105141-71-1

57 105141-71-1

58 105141-71-1

59 105141-71-1

60 105141-71-1

61 105141-71-1

62 105141-71-1

63 105141-71-1

64 105141-71-1

65 105141-71-1

66 105141-71-1

67 105141-71-1

68 105141-71-1

69 105141-71-1

70 105141-71-1

71 105141-71-1

72 105141-71-1

73 105141-71-1

74 105141-71-1

75 105141-71-1

76 105141-71-1

77 105141-71-1

78 105141-71-1

79 105141-71-1

80 105141-71-1

81 105141-71-1

82 105141-71-1

83 105141-71-1

84 105141-71-1

85 105141-71-1

86 105141-71-1

87 105141-71-1

88 105141-71-1

89 105141-71-1

90 105141-71-1

91 105141-71-1

92 105141-71-1

93 105141-71-1

94 105141-71-1

95 105141-71-1

96 105141-71-1


97 105141-71-1

98 105141-71-1

99 105141-71-1

100 105141-71-1

16 ANDER 31 00 100 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



PAGE 1-B

105141-71-1 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE ACS PDB


16 ANDER 32 00 100 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

17 644970-91-0F 644970-91-0F 644970-91-0F
 18 644970-91-0F 644970-91-0F 644970-91-0F
 19 644970-91-0F 644970-91-0F 644970-91-0F

20 RE: ABS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 21 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 22 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 23 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 24 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 25 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 26 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 27 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 28 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 29 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 30 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 31 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 32 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 33 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 34 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 35 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 36 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 37 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 38 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 39 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 40 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 41 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 42 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 43 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 44 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 45 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 46 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 47 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 48 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 49 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 50 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 51 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 52 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 53 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 54 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 55 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 56 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 57 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 58 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 59 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 60 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 61 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 62 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 63 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 64 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 65 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 66 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 67 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 68 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 69 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 70 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 71 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 72 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 73 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 74 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 75 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 76 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 77 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 78 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 79 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 80 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 81 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 82 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 83 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 84 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 85 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 86 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 87 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 88 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 89 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 90 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 91 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 92 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 93 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 94 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 95 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 96 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 97 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 98 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 99 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic
 100 preparation); ACS (Analytical reagent use); FFP (Fluorescence), 2PM (Synthetic


20 644970-91-0F CAPLUS
 21 38-Indolium, 2-[1,6-Bis(3,5-di-tert-butyl-4-methoxy-2,5-dimethyl-1H-pyrid-1-
 22 yl)ethyl]amino-6-methyl-1,3-dihydro-3,5-dimethyl-2H-indol-2-ylidene]-1-
 23 propen-7-yl]-1-ethyl-3,5-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

24 Double bond geometry as shown.



20 644970-91-0F CAPLUS
 21 38-Indolium, 2-[1,6-Bis(3,5-di-tert-butyl-4-methoxy-2,5-dimethyl-1H-pyrid-1-
 22 yl)ethyl]amino-6-methyl-1,3-dihydro-3,5-dimethyl-2H-indol-2-ylidene]-1-
 23 propen-7-yl]-1-ethyl-3,5-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)


24 Double bond geometry as shown.



20 644970-91-0F CAPLUS

21 38-Indolium, 2-[1,6-Bis(3,5-di-tert-butyl-4-methoxy-2,5-dimethyl-1H-pyrid-1-
 22 yl)ethyl]amino-6-methyl-1,3-dihydro-3,5-dimethyl-2H-indol-2-ylidene]-1-
 23 propen-7-yl]-1-ethyl-3,5-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)


24 Double bond geometry as shown.



38 A method set of fluorescent dyes is provided, wherein each dye of the set
 39 is capable of covalent attachment to a protein and wherein each of the
 40 dyes has a mol. structure and a charge that is matched one with the other,
 41 such that relative electrophoretic mobility of a protein labeled with one
 42 dye of the set is the same as the electrophoretic mobility of the protein
 43 labeled with a different dye of the set. The matched set comprises at
 44 least two different fluorescent dyes of formula (I) wherein n is 1, 2, or
 45 3; 1, 2, and 3 independently represent the carbon atoms necessary to
 46 complete a Ph or methyl ring system; one of groups R1 and R2 is a target
 47 binding group, remaining group R1 or R2 is selected from -CH2CH2CH2-
 48 -CH2CH2CH2-CH2CH2CH2- or hydrogen, except when either R1 or R2 is -CH2CH2CH2-
 49 in which case R1 is H, and R2 is a hydrogen, acid and sulfonate.
 50 The invention also provides a method for saturation labeling of a protein with
 51 a fluorescent dye so as to label all available target amino acid, optionally
 52 cysteine, residues in the protein, thereby giving a single population of
 53 labeled protein molecules.

LE AMER 33 OF 100 CAPUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



LE AMER 33 OF 100 CAPUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A

RE CNT 9 THERE ARE 0 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL TEXTURES AVAILABLE IN THE RE F00047LE AMER 34 OF 100 CAPUS COPYRIGHT 2009 ACS on STN
IN 0000-7030(200901)29:00000;1-0

AB Fluorescence properties, thermal duplex stability, and kinetics of formation of cisplatin-DNA adducts
 AU von de Walle, Franz M.; Borek, Robert J.; Talsma, Edward G.; Talsma, Hans J.; Bago, Anton K.
 CS Department Molecular Cell Biology, Leiden University Medical Centre, NL Leiden, 2300, Neth.
 SO Analytical Biochemistry 2009, 321(1), 71-78
 DB ANSCAC; ISSN 0003-2697
 PS Elsevier Science
 JT Journal
 PT Article
 AD


Fluorescent and biotinylated monofunctionally binding platinum compounds are increasingly used for chemical labeling nucleic acids for hybridization detection purposes. Here we analyze in detail the effect of labeling of the guanine and -5 platinum-DNA adducts on fluorescence and thermal stability. We also analyzed the kinetics of the reaction of the cisplatin platinum compounds with DNA. The data provided are important for the design of optimal platinum-DNA labeling and hybridization conditions for fluorescence hybridization applications.

IT 090608-10-01A, reaction products with DNA 090608-01-1A, reaction products with DNA
 RE AB Analytical reagent use; RU (Biological use, unclassified); PNP (Synthetic); ACST (Analytical study); BICM (Biological study); UBBE (Use);
 (Use);

Fluorescence properties, thermal duplex stability, and kinetics of formation of cisplatin-DNA adducts

IN 090608-01-01A CAPUS

AB Fluorescence properties, thermal duplex stability, and kinetics of formation of cisplatin-DNA adducts
 AU von de Walle, Franz M.; Borek, Robert J.; Talsma, Edward G.; Talsma, Hans J.; Bago, Anton K.
 CS Department Molecular Cell Biology, Leiden University Medical Centre, NL Leiden, 2300, Neth.
 SO Analytical Biochemistry 2009, 321(1), 71-78
 DB ANSCAC; ISSN 0003-2697
 PS Elsevier Science
 JT Journal
 PT Article
 AD





● HCl

IN 090608-01-01A CAPUS

AB Fluorescence properties, thermal duplex stability, and kinetics of formation of cisplatin-DNA adducts
 AU von de Walle, Franz M.; Borek, Robert J.; Talsma, Edward G.; Talsma, Hans J.; Bago, Anton K.
 CS Department Molecular Cell Biology, Leiden University Medical Centre, NL Leiden, 2300, Neth.
 SO Analytical Biochemistry 2009, 321(1), 71-78
 DB ANSCAC; ISSN 0003-2697
 PS Elsevier Science
 JT Journal
 PT Article
 AD

LE AMER 34 OF 100 CAPUS COPYRIGHT 2009 ACS on STN (Continued)




● HCl


RE CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL TEXTURES AVAILABLE IN THE RE F00047

LE ANDER 42 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-5



PAGE 2-A



LE ANDER 42 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 3-B




CM 2

CIN 497944-66-d

COT C106 H135 N19 019 32


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




LE ANDER 42 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-B




PAGE 3-A




LE ANDER 42 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



PAGE 3-B



LE NUMBER 43 OF 100 CAPSULE COPYRIGHT 2008 ACS ON STN
 AK 0000-141222 CAPSULE
 IN US-162621

TI FRET-based detection of nucleic acids using luminescent indicators with high affinity for multiple nucleic acid complex

IN Nakamura, Takashi; Wakino, Yoshitaka
 PA Fuji Photo Film Co., Ltd., Japan

SO 01st Kokai Tokyo Kobo, 11 pp

DE Patent

LA Japanese

PAN CNT 3

PATENT NO.	SENO	DATE	APPLICATION NO.	DATE
P1	JP 2000-047038	A	200006025	JP 2000-047038
	US 2000/0691818	A1	US 2000/069094	US 2000-210671
PRAT	JP 2000-047038	A	2000/06917	200006016
	JP 2000-047038	A	2000/06917	200006016
	JP 2000-047038	A	2000/06917	200006016

AB A method for detection of nucleic acids using hybridization probes and at least a pair of luminescent comds, having higher affinity for duplex or triplex nucleic acid complex than to single-stranded forms are described. The luminescent comds. are intercalating agents and have at least a pair of fluorophores whose absorption/emission wavelength are separated by 80nm. Fluorescent comds. of this invention provided a much higher signal to noise ratio due to fluorescence resonance energy transfer (FRET) compared to the reference comds. when used in combination with immobilized probes. A method for detection of nucleic acids using hybridization probes and at least a pair of luminescent comds, having higher affinity for duplex or triplex nucleic acid complex than to single-stranded forms are described. At least one of the luminescent comds. is an intercalating agent. Fluorescent comds. of this invention provided a much higher signal to noise ratio due to fluorescence resonance energy transfer (FRET) compared to the reference comds. when used in combination with immobilized probes.

IT 69221-47-1
 RE ABS (Analytical reagent use); ANST (Analytical study); USBS (Uses)
 (FRET-based detection of nucleic acids using luminescent indicators with high affinity for multiple nucleic acid complex)

IN 69221-47-1 CAPSULE
 CN 692-Indium, 1,1'-(1,3,4,8-tetrahydro-1,3,6,8-tetrazaphenanthro[9,10-b]indole-2,7-diyl)bis[3,1-propenyl] (hexylamino)-5,1'-propanediylimino-4'-oxo-6,1'-benzodipyr[1]bis[2-[5-(4-ethyl-1,3-dihydro-2,3-dimethyl-2-sulfo-2H-indol-2-ylidene)-1-propenyl]-2,3-dimethyl-2-sulfo-, bis(dimer salt), dipotassium salt (PC) (CA INDEX NAME)

LE NUMBER 44 OF 100 CAPSULE COPYRIGHT 2008 ACS ON STN
 AK 0000-141222 CAPSULE
 IN US-162621

TI FRET-based detection of nucleic acids using luminescent indicators with high affinity for multiple nucleic acid complex

IN Nakamura, Takashi; Wakino, Yoshitaka
 PA Fuji Photo Film Co., Ltd., Japan

SO 01st Kokai Tokyo Kobo, 12 pp

DE Patent

LA Japanese

PAN CNT 3


PATENT NO.	SENO	DATE	APPLICATION NO.	DATE
P1	JP 2000/047038	A	200006025	JP 2000-047038
	US 2000/0691818	A1	US 2000/069094	US 2000-210671
PRAT	JP 2000-047038	A	2000/06917	200006016
	JP 2000-047038	A	2000/06917	200006016
	JP 2000-047038	A	2000/06917	200006016

AB A method for detection of nucleic acids using hybridization probes and at least a pair of luminescent comds, having higher affinity for duplex or triplex nucleic acid complex than to single-stranded forms are described. At least one of the luminescent comds. is an intercalating agent. Fluorescent comds. of this invention provided a much higher signal to noise ratio due to fluorescence resonance energy transfer (FRET) compared to the reference comds. when used in combination with immobilized probes.

IT 69221-48-0 69221-47-1
 RE ABS (Analytical reagent use); ANST (Analytical study); USBS (Uses)
 (FRET-based detection of nucleic acids using luminescent indicators with high affinity for multiple nucleic acid complex)

IN 69221-48-0 CAPSULE
 CN 692-Indium, 1,1'-(1,3,4,8-tetrahydro-1,3,6,8-tetrazaphenanthro[9,10-b]indole-2,7-diyl)bis[3,1-propenyl] (hexylamino)-5,1'-propanediylimino-4'-oxo-6,1'-benzodipyr[1]bis[2-[5-(4-ethyl-1,3-dihydro-2,3-dimethyl-2-sulfo-2H-indol-2-ylidene)-1-propenyl]-2,3-dimethyl-2-sulfo-, bis(dimer salt), dipotassium salt (PC) (CA INDEX NAME)


PAGE 1-A



● K


LE NUMBER 45 OF 100 CAPSULE COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




● K

PAGE 1-B



LE NUMBER 44 OF 100 CAPSULE COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-B




PAGE 1-C



IN 69221-47-1 CAPSULE
 RE-Indium, 1,1'-(1,3,4,8-tetrahydro-1,3,6,8-tetrazaphenanthro[9,10-b]indole-2,7-diyl)bis[3,1-propenyl] (hexylamino)-5,1'-propanediylimino-4'-oxo-6,1'-benzodipyr[1]bis[2-[5-(4-ethyl-1,3-dihydro-2,3-dimethyl-2-sulfo-2H-indol-2-ylidene)-1-propenyl]-2,3-dimethyl-2-sulfo-, bis(dimer salt), dipotassium salt (PC) (CA INDEX NAME)


PAGE 1-A



● K

LE NUMBER 45 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B



LE NUMBER 45 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2000 141250 CAPLUS

IN 135 100250

TI FRET-based detection of nucleic acids using fluorescent indicators with high affinity for multiple nucleic acid complex.

IN Nakamura, Takemura

PR Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

COWY JXKXN

IN Patent

LA Japanese

PAN CXT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000061000	A	20000625	JP 2000-240255	20010811 (---)
JP 2000061018	A1	20000625	JP 2000-240255	20010816 (---)
FR01-247532	A	20010817		
JP 2001-247532	A	20010817		
JP 2001-247538	A	20010817		

AB A method for detection of nucleic acids using hybridization probes and at least a salt of fluorescent complex having higher affinity for duplex or triplex nucleic acid complex than to single-stranded forms are described. At least one of the fluorescent complex is an intercalating agent. Fluorescent complex of this invention provided a much higher signal to noise ratio due to fluorescence resonance energy transfer (FRET) compared to the reference complex when used in combination with immobilized probe.

IT 492227-46-0 492227-47-1 492227-48-2

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators


EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

FRIT-based detection of nucleic acids using fluorescent indicators

EL AND analytical reagent use; ANET (Analytical study); REES (Rees)

LE NUMBER 45 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B




PAGE 1-C



IN 492227-47-1 CAPLUS

OX 5,6-tetrahydro-1,1'-[2,2'-(1,3,5,6-tetrahydro-1,3,6,8-tetraazabenzothiazine-2,7-diyl)]bis[3,1'-quinoxaline-2-carboxamide-5,8-dimethyl-2-ylidene-1,3-pyridinediyl]-3,5-dimethyl-6-sulfonate, bis(tartrate salt) (CCT) (CA INDEX NAME)


PAGE 1-A



● K

LE NUMBER 45 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


PAGE 1-B




IN 492227-48-2 CAPLUS

OX 5,6-tetrahydro-1,1'-[2,2'-(1,3,5,6-tetrahydro-1,3,6,8-tetraazabenzothiazine-2,7-diyl)]bis[3,1'-quinoxaline-2-carboxamide-5,8-dimethyl-2-ylidene-1,3-pyridinediyl]-3,5-dimethyl-6-sulfonate, bis(tartrate salt) (CCT) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



LE ANSWER 46 OF 100 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)
PAGE 1-C



LE ANSWER 46 OF 100 CAPLUS COPYRIGHT 2000 ACS on STN
AN 2000 141223 CAPLUS
IN 135 100249
T1 Fluorescent indicators with high affinity for multiples nucleic acid
complexes for detection of nucleic acids via hybridization
IN Nakazawa, Takaki
PR Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 12 jp)
OOBY JKKAN
BT Patent
LA Japanese
PAN CNT


PATENT NO.	END DATE	APPLICATION NO.	DATE
JP 2000060517	A	20000628	20070817 (-)
JP 2000-241251		20000617	

AS A method for detection of nucleic acids using hybridization probes and at least a pair of fluorescent indicators having higher affinity for duplex or triplex nucleic acid complex than to single stranded forms are described. Fluorescent complex of this invention provided a much higher signal to noise ratio compared to the reference complex, when used in combination with immobilized probes.

IT 692217-4P-0 692217-4P
RE AND deslabeled reagent use), ANET (Analytical study); REES (Rees)
(Fluorescent indicators with high affinity for multimeric nucleic acid complex for detection of nucleic acids via hybridization)

IN 692217-4P-0 CAPLUS
CN CD-Indium, 1,1'-(1,3,4,8-tetrahydro-1,5,6,8-tetracarboxyphenyl[2,3-bisphenanthroline-2,7-diyl]bis[4,1'-spiro[5,5]undec-10-en-2-yl-1'-propenyl]bis[6-methoxy-4,1-benzopyridyl]]bis[2-(5-(4-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,5-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl] (CA INDEX NAME)


PAGE 1-A



● K

LE ANSWER 46 OF 100 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

PAGE 1-B




PAGE 1-C



IN 692217-67-1 CAPLUS
BT-Indium, 1,1'-(1,3,4,8-tetrahydro-1,5,6,8-tetracarboxyphenyl[2,3-bisphenanthroline-2,7-diyl]bis[4,1'-spiro[5,5]undec-10-en-2-yl-1'-propenyl]bis[6-methoxy-4,1-benzopyridyl]]bis[2-(5-(4-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,5-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl] (CA INDEX NAME)


PAGE 1-A




● K

LE ANSWER 46 OF 100 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

PAGE 1-B



LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A


PAGE 1-B

~SO₃⁻

BN S1062-96-5 CAPLUS
CN Adenosine 5'-triphosphate (ATP), 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-5,3-dimethyl-2-oxo-2H-indol-2-ylidene)-1-oxopropyl]-3,3'-dimethyl-5'-oxo-5H-spiro[5.5]undec-1-yn-1-yl)aminoethyl]carbamate], inner salt (XCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A


PAGE 1-B

~SO₃⁻

BN S1062-96-5 CAPLUS
CN Adenosine 5'-triphosphate (ATP), 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-5,3-dimethyl-2-oxo-2H-indol-2-ylidene)-1-oxopropyl]-3,3'-dimethyl-5'-oxo-5H-spiro[5.5]undec-1-yn-1-yl)aminoethyl]carbamate], inner salt (XCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A


PAGE 1-B

~SO₃⁻

IT S1062-96-5A CAPLUS
CN Adenosine 5'-triphosphate (ATP), 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-5,3-dimethyl-2-oxo-2H-indol-2-ylidene)-1-oxopropyl]-3,3'-dimethyl-5'-oxo-5H-spiro[5.5]undec-1-yn-1-yl)aminoethyl]carbamate], inner salt (XCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A

PAGE 1-B


~SO₃⁻

BN S1062-96-5 CAPLUS
CN Adenosine 5'-triphosphate (ATP), 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-5,3-dimethyl-2-oxo-2H-indol-2-ylidene)-1-oxopropyl]-3,3'-dimethyl-5'-oxo-5H-spiro[5.5]undec-1-yn-1-yl)aminoethyl]carbamate], inner salt (XCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


~50~

BN 521462-99-5 CAPLUS
 CN Metocaine 5'-trifluoromethyladenosine, 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-3,5-dimethyl-2H-pyrido[2H]-indol-2-ylidene)-1-methyl-3,3'-diacetyl-5'-phosphoribitol-5'-oxyethyl)-oxyethyl]carbamate], inner salt (XCD) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


~50~

BN 521462-99-5 CAPLUS
 CN Metocaine 5'-trifluoromethyladenosine, 2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-3,5-dimethyl-2H-pyrido[2H]-indol-2-ylidene)-1-methyl-3,3'-diacetyl-5'-phosphoribitol-5'-oxyethyl)-oxyethyl]carbamate], inner salt (XCD) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

~50~

RE CNT 20 THERE ARE NO CITATION REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE POINT

LE ANDER 48 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN

BN 2002-24069 CAPLUS

IN 159-2532

IN 159-2532

AI Bertram, V.; Loughhead, T.; Henne, J.; Furedi-Kimmler, E.; Pettig, N.; Beltranda, J. C.; Woolley, G. A.; Schott, G. J. Department of Chemistry, University of Toronto, Toronto, ON, M5S 3M6, Can.

CS Biophysical Journal (2006), 94(1), 612-622

CCDC 630040; CCDC 6066-1499

FB Biophysical Society

BT Journal

LA Shellol

QC CASREACT 159-2532

AB We report here an approach for simultaneous fluorescence imaging and elec- recording of single ion channels in planar bilayer membranes. As a test case, fluorescently labeled Cy3 and Cy5 gramicidin deriva- were imaged at the single-mol- level using far-field illumination and cooled CCD camera detection. Gramicidin monomers were observed to diffuse in the plane of the membrane with a diffusion coefficient of 5.5×10^{-6} cm²/s. Simultaneous elec- recording detected gramicidin conductance (Cy3/Cy5, Cy5/Cy5) and heterodimer (Cy3/Cy5) channels. Heterodimer formation was observed optically by the appearance of a fluorescence resonance energy transfer (FRET) signal (irradiation of Cy3, detection of Cy5). The number of FRET signals was significantly smaller than the number of Cy3 signals (Cy3 monomers plus Cy5 homodimers) as expected. The number of FRET signals increased with increasing channel activity. In numerous cases the appearance of a FRET signal was observed to correlate with a channel opening event detected elec-. The heterodimers also diffused in the plane of the membrane with a diffusion coefficient of 5.0×10^{-6} cm²/s. These results demonstrate the feasibility of simultaneous optical and elec- detection of structural changes in single ion channels as well as suggesting strategies for improving the reliability of such measurements.

IT 52461-1-2P 52461-1-5-4P
 H. RCU (Biological study, unclassified); BNU (Biological use, unclassified); SYN (Synthetic preparation); BNU (Biological study); PSP (Preparation); BNU (Use) (simultaneous optical and elec- recording method permits anal- of single gramicidin channels in planar bilayer membranes)


BN 52461-1-2 CAPLUS

CN Gramicidin A, 1'-[6-[trifluoromethyladenosine]-1E-DN-2'-[2-[(6-[2-[(1E,3E)-5-(1-ethyl-1,3-dihydro-3,5-dimethyl-2H-pyrido[2H]-indol-2-ylidene)-1,3,5-pentadienyl-3,3'-diacetyl-5'-phosphoribitol-5'-oxyethyl)-oxyethyl]carbamate]]aminoethyl]aminoethyl-2'-tryptophanamide], inner salt (XCD) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

U6 ANSWER 49 OF 109 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 3-A




PAGE 1-B




L6 ANSWER 49 OF 100 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




PAGE 1-C



16 ANSWER 49 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-C



PAGE 1-D




RN 634614-55-6 CAPLIS
 CN Gramicidin A, 1-L-valine-15-[N-[2-[[[3-[[6-[[2-[3-(1-ethyl-1,3-dihydro-2,3,5-trimethyl-5-sulfo-2H-indol-2-ylidene)]-n-oxenyl]-3,3-dimethyl-5-sulfo-3H-indolol-1-yl-oxobutyl]amino]ethyl]amino]ethyl]-L-tryptophanamide]-, inner salt (9CI) (CA INORG NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE SE FORMAT

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE FE FORMAT

L6 ANSWER 50 OF 109 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 1-A



PAGE 1-B



RW 477885-58-8 CAPLIS
 CN 1H-Benz[e]indolium, 2-[3-[3-[6-[(3-carboxypropyl)amino]-6-oxobenzyl]-1,3-dihydro-1,1-dimethyl-7-sulfo-2H-benz[e]indo]-2-ylidene]-1-propen-1-yl]-3-ethyl-1,1-dimethyl-7-sulfor, inner salt, cesium potassium salt (1:1:1)
 (CA INDEX NAME)

E6 ANSWER 51 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN

AN	2000-040605	CAPLUS
DN	137-364341	
TI	Large-scale sequencing of nucleic acids captured on arrays by cyclic addition of base analogs with labile reporter groups blocking primer	

extension
IN Toberkassov, Dnestro
PA Genovox G.m.b.H., Germany
CO DCT Ind Appl 123 pp

DE Patent
LA German
BAN.CMT 1

P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	P21	P22	P23	P24	P25	P26	P27	P28	P29	P30	P31	P32	P33	P34	P35	P36	P37	P38	P39	P40	P41	P42	P43	P44	P45	P46	P47	P48	P49	P50	P51	P52	P53	P54	P55	P56	P57	P58	P59	P60	P61	P62	P63	P64	P65	P66	P67	P68	P69	P70	P71	P72	P73	P74	P75	P76	P77	P78	P79	P80	P81	P82	P83	P84	P85	P86	P87	P88	P89	P90	P91	P92	P93	P94	P95	P96	P97	P98	P99	P100	P101	P102	P103	P104	P105	P106	P107	P108	P109	P110	P111	P112	P113	P114	P115	P116	P117	P118	P119	P120	P121	P122	P123	P124	P125	P126	P127	P128	P129	P130	P131	P132	P133	P134	P135	P136	P137	P138	P139	P140	P141	P142	P143	P144	P145	P146	P147	P148	P149	P150	P151	P152	P153	P154	P155	P156	P157	P158	P159	P160	P161	P162	P163	P164	P165	P166	P167	P168	P169	P170	P171	P172	P173	P174	P175	P176	P177	P178	P179	P180	P181	P182	P183	P184	P185	P186	P187	P188	P189	P190	P191	P192	P193	P194	P195	P196	P197	P198	P199	P200	P201	P202	P203	P204	P205	P206	P207	P208	P209	P210	P211	P212	P213	P214	P215	P216	P217	P218	P219	P220	P221	P222	P223	P224	P225	P226	P227	P228	P229	P230	P231	P232	P233	P234	P235	P236	P237	P238	P239	P240	P241	P242	P243	P244	P245	P246	P247	P248	P249	P250	P251	P252	P253	P254	P255	P256	P257	P258	P259	P260	P261	P262	P263	P264	P265	P266	P267	P268	P269	P270	P271	P272	P273	P274	P275	P276	P277	P278	P279	P280	P281	P282	P283	P284	P285	P286	P287	P288	P289	P290	P291	P292	P293	P294	P295	P296	P297	P298	P299	P300	P301	P302	P303	P304	P305	P306	P307	P308	P309	P310	P311	P312	P313	P314	P315	P316	P317	P318	P319	P320	P321	P322	P323	P324	P325	P326	P327	P328	P329	P330	P331	P332	P333	P334	P335	P336	P337	P338	P339	P340	P341	P342	P343	P344	P345	P346	P347	P348	P349	P350	P351	P352	P353	P354	P355	P356	P357	P358	P359	P360	P361	P362	P363	P364	P365	P366	P367	P368	P369	P370	P371	P372	P373	P374	P375	P376	P377	P378	P379	P380	P381	P382	P383	P384	P385	P386	P387	P388	P389	P390	P391	P392	P393	P394	P395	P396	P397	P398	P399	P400	P401	P402	P403	P404	P405	P406	P407	P408	P409	P410	P411	P412	P413	P414	P415	P416	P417	P418	P419	P420	P421	P422	P423	P424	P425	P426	P427	P428	P429	P430	P431	P432	P433	P434	P435	P436	P437	P438	P439	P440	P441	P442	P443	P444	P445	P446	P447	P448	P449	P450	P451	P452	P453	P454	P455	P456	P457	P458	P459	P460	P461	P462	P463	P464	P465	P466	P467	P468	P469	P470	P471	P472	P473	P474	P475	P476	P477	P478	P479	P480	P481	P482	P483	P484	P485	P486	P487	P488	P489	P490	P491	P492	P493	P494	P495	P496	P497	P498	P499	P500	P501	P502	P503	P504	P505	P506	P507	P508	P509	P510	P511	P512	P513	P514	P515	P516	P517	P518	P519	P520	P521	P522	P523	P524	P525	P526	P527	P528	P529	P530	P531	P532	P533	P534	P535	P536	P537	P538	P539	P540	P541	P542	P543	P544	P545	P546	P547	P548	P549	P550	P551	P552	P553	P554	P555	P556	P557	P558	P559	P560	P561	P562	P563	P564	P565	P566	P567	P568	P569	P570	P571	P572	P573	P574	P575	P576	P577	P578	P579	P580	P581	P582	P583	P584	P585	P586	P587	P588	P589	P590	P591	P592	P593	P594	P595	P596	P597	P598	P599	P600	P601	P602	P603	P604	P605	P606	P607	P608	P609	P610	P611	P612	P613	P614	P615	P616	P617	P618	P619	P620	P621	P622	P623	P624	P625	P626	P627	P628	P629	P630	P631	P632	P633	P634	P635	P636	P637	P638	P639	P640	P641	P642	P643	P644	P645	P646	P647	P648	P649	P650	P651	P652	P653	P654	P655	P656	P657	P658	P659	P660	P661	P662	P663	P664	P665	P666	P667	P668	P669	P670	P671	P672	P673	P674	P675	P676	P677	P678	P679	P680	P681	P682	P683	P684	P685	P686	P687	P688	P689	P690	P691	P692	P693	P694	P695	P696	P697	P698	P699	P700	P701	P702	P703	P704	P705	P706	P707	P708	P709	P710	P711	P712	P713	P714	P715	P716	P717	P718	P719	P720	P721	P722	P723	P724	P725	P726	P727	P728	P729	P730	P731	P732	P733	P734	P735	P736	P737	P738	P739	P740	P741	P742	P743	P744	P745	P746	P747	P748	P749	P750	P751	P752	P753	P754	P755	P756	P757	P758	P759	P760	P761	P762	P763	P764	P765	P766	P767	P768	P769	P770	P771	P772	P773	P774	P775	P776	P777	P778	P779	P780	P781	P782	P783	P784	P785	P786	P787	P788	P789	P790	P791	P792	P793	P794	P795	P796	P797	P798	P799	P800	P801	P802	P803	P804	P805	P806	P807	P808	P809	P810	P811	P812	P813	P814	P815	P816	P817	P818	P819	P820	P821	P822	P823	P824	P825	P826	P827	P828	P829	P830	P831	P832	P833	P834	P835	P836	P837	P838	P839	P840	P841	P842	P843	P844	P845	P846	P847	P848	P849	P850	P851	P852	P853	P854	P855	P856	P857	P858	P859	P860	P861	P862	P863	P864	P865	P866	P867	P868	P869	P870	P871	P872	P873	P874	P875	P876	P877	P878	P879	P880	P881	P882	P883	P884	P885	P886	P887	P888	P889	P890	P891	P892	P893	P894	P895	P896	P897	P898	P899	P900	P901	P902	P903	P904	P905	P906	P907	P908	P909	P910	P911	P912	P913	P914	P915	P916	P917	P918	P919	P920	P921	P922	P923	P924	P925	P926	P927	P928	P929	P930	P931	P932	P933	P934	P935	P936	P937	P938	P939	P940	P941	P942	P943	P944	P945	P946	P947	P948	P949	P950	P951	P952	P953	P954	P955	P956	P957	P958	P959	P960	P961	P962	P963	P964	P965	P966	P967	P968	P969	P970	P971	P972	P973	P974	P975	P976	P977	P978	P979	P980	P981	P982	P983	P984	P985	P986	P987	P988	P989	P990	P991	P992	P993	P994	P995	P996	P997	P998	P999	P1000

AS MARPAT 187-564841


AS The invention relates to a method for large-scale parallel sequencing of nucleic acids. The method involves capturing individual sequences in an array using oligonucleotides that can be used as hybridization probes and primers. Sequences are captured on an array and sequences are determined by primer extension using base analogs carrying a labile reporter group that blocks primer extension. After determining the incorporated base, e.g. by fluorimetry, the blocking group is removed and rounds of base

incorporation are repeated.
IT 474908-47-9 474908-49-1
RL: ASO (Analytical reagent use); ANST (Analytical study); USRS (Uses)
(in DNA sequencing; large-scale sequencing of nucleic acids captured on
arrays by cyclic addition of base analogs with labile reporter groups
blocking primer extension)


474008-47-9 CAPLUG
3H-Indolium, 2-[3-{1-[6-{[2-{[1-[2-deoxy-5- β -[hydroxy[[hydroxy(phosphonoxy)thiosilyl]oxy]phosphoryl]- β -D-erythro-pentofuranosyl]-1, 2, 3, 4-tetrahydro-2, 4-dioxo-5- β -imidazole]di thio]ethyl]amino]-6-isobutyl]-1, 3-dihydro-2, 3-dimethyl-5-sulfo-2H-imidazo[2- γ]idene]-1-propen-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt. (CA INDEX NAME)

Absolute stereochemistry—
Double bond geometry unknown

16 ANSWER 50 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)



LE ANSWER 51 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-1



PAGE 1-3

2H-Indolium, 2-[3-(1-[6-[[2-[[4-amino-1-[2-deoxy-5-
 [hydroxy[[hydroxy(phosphonoxy)phosphoryl]oxy]hydropyridin-1- β -D-erythro-
 pentofuranosyl]-1], 2-dihydro-2-oxo-5-pyrimidinyl]dithio]ethyl]amino]-6-oxo-
 hexyl]-1,3-dihydro-3,3-dimethyl-6-sulfo-2H-indol-2-ylidene]-1-propen-1-
 yl]-1-ethyl]-3,3-dimethyl-6-sulfo-, inner salt. (CA INDEX NAME)

Absolute stereochemistry
Double bond geometry unknown





```

IT 45E253-00-SP
RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation;
    (Reactant or reagent)
    (glutamine compds. for nucleic acid labeling)
RN 45E253-00-5 CAPLUS
CN 33-Indolium, 2-[6-[1-[6-[(6-aminohexyl)amino]-6-oxohexyl]-1,3-dihydro-
    dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,
    dimethyl-5-sulfo-, inner salt (CA INDEX NAME)



```

$$\text{H}_2\text{N}-(\text{CH}_2)_6-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-(\text{CH}_2)_5$$

LE ANDER ET OF 100 CAPUS COPYRIGHT 2008 ACS ON STN (Continued)




IN 441068-14-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl-1,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)



IN 441068-15-1 CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl-1,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)

LE ANDER ET OF 100 CAPUS COPYRIGHT 2008 ACS ON STN (Continued)



PAGE 1-A




PAGE 1-B



LE ANDER ET OF 100 CAPUS COPYRIGHT 2008 ACS ON STN (Continued)



IT 441068-06-Q
 RE RCT (Reactant); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-06-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)



IT 441068-12-Q
 RE RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-12-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)

LE ANDER ET OF 100 CAPUS COPYRIGHT 2008 ACS ON STN

PAGE 1-A

IN 441068-12-Q
 RE RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-12-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)


IN 441068-12-Q
 RE RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-12-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)

IN 441068-12-Q
 RE RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-12-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)

IN 441068-12-Q
 RE RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 COUPLING WITH ISOTHIOCYANATE/ISOTHIOCYANATE TRIFLUOROACETAMIDE
 IN 441068-12-Q CAPUS
 ON SE Isobutylam, 2-[6-[[1,3-dihydro-3,5-dimethyl-1-[6-[[2-[[4-[[4-(3-methylphenyl)phenyl]]-1-oxoethyl]amino]ethyl]amino]-6-sulfamoyl]-2-pyridenyl]-3-methoxyethyl-7-yl]-3-ethyl-5,3-dimethyl-5-sulfamoyl, inner salt (CA INDEX NAME)

ANALYZE STEREOCHEMISTRY
 DOUBLE BOND GEOMETRY UNKNOWN

PAGE 1-A



LE ANKER 58 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

LE ANKER 58 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-5

PAGE 1-5



IN 256743-46-1 CAPLUS
ON 3H-Indolium, 2-[2-[1-[6-[[2-[2-amino-4,7-dihydro-4-oxo-7-[(2R,6S)-tetrahydro-5-[[1-hydroxy[[hydroxy(hydrophenoxy)phosphoryl]oxy]phosphoryl]oxy]methyl]-2-furanyl]-2H-pyridin-2-yl]-2-pyrimidin-5-yl]-2-pyrimidin-5-ylamino]-6-methyl-1,3-dihydro-1,1-dimethyl-4,8-difluoro-3H-benzal]indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfonate, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.





IN 256743-46-1 CAPLUS
ON 3H-Indolium, 2-[2-[1-[6-[[2-[2-amino-4,7-dihydro-4-oxo-7-[(2R,6S)-tetrahydro-5-[[1-hydroxy[[hydroxy(hydrophenoxy)phosphoryl]oxy]phosphoryl]oxy]methyl]-2-furanyl]-2H-pyridin-2-yl]-2-pyrimidin-5-yl]-2-pyrimidin-5-ylamino]-6-methyl-1,3-dihydro-1,1-dimethyl-4,8-difluoro-3H-benzal]indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfonate, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A

PAGE 1-A



LE ANKER 58 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

LE ANKER 58 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-5

PAGE 1-5



IN 256743-47-2 CAPLUS
ON 3H-Indolium, 2-[2-[1-[6-[[2-[2-amino-7-[(2R,6S)-tetrahydro-5-[[1-hydroxy[[hydroxy(hydrophenoxy)phosphoryl]oxy]phosphoryl]oxy]methyl]-2-furanyl]-2H-pyridin-2-yl]-2-pyrimidin-5-yl]-2-pyrimidin-5-ylamino]-6-methyl-1,3-dihydro-1,1-dimethyl-4,8-difluoro-3H-benzal]indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfonate, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.





IN 256743-48-3 CAPLUS
ON 3H-Indolium, 2-[2-[1-[6-[[2-[2-amino-1,2-dihydro-2-oxo-1-[(2R,6S)-tetrahydro-5-[[1-hydroxy[[hydroxy(hydrophenoxy)phosphoryl]oxy]phosphoryl]oxy]methyl]-2-furanyl]-2-pyrimidin-5-yl]-2-pyrimidin-5-ylamino]-6-methyl-1,3-dihydro-1,1-dimethyl-4,8-difluoro-3H-benzal]indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfonate, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A

PAGE 1-A




PAGE 1-5

IN 256743-49-4 CAPLUS
ON 3H-Indolium, 2-[2-[1-[3,5-dihydro-3,3-dimethyl-1-[6-oxo-6-[[6-oxo-6-[[5-(1,2,3,4-tetrahydro-2,4-dioxo-1-[(2R,6S)-tetrahydro-5-[[1-hydroxy[[hydroxy(hydrophenoxy)phosphoryl]oxy]phosphoryl]oxy]methyl]-2-furanyl]-2-pyrimidin-5-yl]-2-pyrimidin-5-ylamino]-6-methyl-1,3-dihydro-1,1-dimethyl-4,8-difluoro-3H-benzal]indol-2-ylidene]-1,3-pentadien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfonate, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


LE ANDER 59 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 oxido-16,17-dioxo-2-one-9,16-diazep-1-yl]imidyl-
 2'-deoxy-2'-oxoethyl-1'-[3'-deoxy-3'-[4-
 methoxyphenyl]-2'-oxopropyl]amino-2'-deoxy-N,N-dimethyl- (DC1) (CA INDEX NAME)

Absolute stereochemistry
 Double bond geometry unknown



PAGE 1-A


PAGE 1-B



LE ANDER 59 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 PAGE 1-C



PAGE 2-A



PAGE 2-B




IN 60083-91-9 CAPLUS
 ON Amino[2, 6'-[6'-[[[6'-[[[3,4,5,6,4,6]-2-amino-3, 4, 6, 6-tetrahydro-1H-
 thiazolo[5, 4-d]imidazo[4, 5-b]pyridine-2-yl]-1'-oxopropyl]amino]hexyl]oxy]hydroxypropyl]-
 2'-deoxy-3'-[6'-[[[6'-[[[3'-[1'-ethoxy]-1,3-dihydro-5,5-dimethyl-4-sulfo-2H-
 imidazo[2, 1-b]furan-2,2'-methylene]-5,5'-dimethyl-4-sulfo-5H-pyridino]-1'-
 oxohexyl]amino]hexyl]amino-2'-oxo-1'-oxopropyl]imidyl-1'-[3'-deoxy-3'-[4-
 methoxyphenyl]-2'-oxopropyl]amino-2'-deoxy-N,N-dimethyl-, inner salt (DC1) (CA INDEX NAME)

Absolute stereochemistry
 Double bond geometry unknown


LE ANDER 59 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A

Ref




PAGE 1-B



LE ANDER 59 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



IN CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

U6 ANSWER 6) OF 109 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-C



PAGE 2-11



PAGE 2-C




IN 408495-35-4 CASREG
 CN L-threonine, 2S-[6-[2-[(1R,3R)-3-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-5-sulfo-3H-indolol]-3-oxohexyl]-N2-[(3R)-fluoro-9-ylmethoxy]carbonyl]-L-lysyl-L-alanyl-L-leucyl-, inner salt (9CI) (CA INDEX NAME)


Absolute stereochemistry
Double bond geometry as shown

L6 ANSWER 61 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-15



PAGE 2-A



II 408493-31-2P
RE: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(div-labeled peptide and method)

```


CN 406408-31-2 CAPLOS
CN 3H-Indolium, 1-[8-[[[8S]-8-carboxy-5-[[[9H-f]uoren-9-ylmethyl]carboxyl]amino]perityl]amino]-6-octoxy]-2-[[[1S,3S]-3-(1-ethyl)-1,3-dihydro-3,3-dimethyl-6-oxo-1H-indol-2-ylidene]-1-propen-1-yl]-3,3-dimethyl-8-sulfo-, inner salt. (CA INDEX NAME)

```

Absolute stereochemistry
Double bond geometry as shown


L6 ANSWER 61 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)

AGE 1-A


$$\begin{array}{c} \text{Me} \quad \text{R} \\ | \quad | \\ \text{C} \\ | \\ \text{H} \end{array}$$

16 ANSWER 61 OF 100 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

(Cost in use)



LG ANSWER 66 OF 67 CAPLUS COPYRIGHT 2009 ACS ON STM
 AN 2001-5001799 CAPLUS
 IN 1318-90921
 DT Mobility-modifying cyanine dyes
 H Hoshino, Steven N. Benson, Scott C. Rosenblum, Barnett B. Khan, Shashank
 PA PE Corporation, USA
 SO PCT Int Appl., 133 pp
 OO OXON FLEX
 DT Patent
 LA English
 PAN CNT 1
 KIND TWAR APPLICATION NO TWAR

[illegible][illegible]

LE ANSWER 66 OF 100 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown

LE ANSWER 66 OF 100 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)

Chemical structure of compound 1, a phthalocyanine derivative. It features a central magnesium atom coordinated by four nitrogen atoms in a phthalocyanine ring. The ring is substituted with a 4-ethoxybenzoyl group at the 3-position and a 5,10-dimethyl-2,2'-biphenyl group at the 1-position. The structure is labeled with 'Me' for methyl groups and '(EtO)' for the ethoxy group.

PAGE 2-3

$\begin{matrix} H \\ | \\ O \\ | \\ OH \end{matrix}$

IR 3496(91)-74-3 CAPLES

CN 1H-Benz[e]indolizin, 2-[5-[3-[6-[[[2-[3-[2-amino-4,7-dihydro-4-oxo-1-(2R,5S)-tetrahydro-6-(3,5,7,7-tetrahydroxy-5,6,7-trioxido-2,4,6-b-tetra-3,4,7-trisuboxy-1-yl)-2-furanyl]-3H-pyrrolo[2,3-d]pyrimidin-8-yl]-2-propen-1-yl]oxyethyl]amino]-6-naphoxy]-1,2-dihydro-1,4-dimethyl-2H-benz[e]indol-2-yl]idene]-2,3-pentadien-1-yl]-1,2-dimethyl-5-(3-sulfoxy)-

LE ANSWER 66 OF 700 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 7-tetradecyl-1-yl-1,3-pentadien-1-yl-1,1-dimethyl-3-sulfopropyl-
 furanyl-2-primidiny-2-propargyl-1-yl-oxethylamino-hexyl-2e-
 benzyl-1-indol-1-ylidene-1,3-pentadien-1-yl-1,1-dimethyl-3-sulfopropyl-
 . inner salt (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry unknown.

IR 3490.91-78.7 cm^{-1} CAPLUS


HN 1H-NMR: [c] in DMSO, 2-[5-[1,3-dihydro-1,1-dimethyl-3-(6-oxo-6-[(2-[(3-[1,2,5,4-tetrahydro-2,6-dioxo-1-[(3R,5S)-tetrahydro-5-(3,5,7,7-

PAGE 1-1

The chemical structure shows a repeating unit of a poly(amide-imine). The backbone consists of an amide linkage (-NH-) connected to an imine ring (a six-membered ring with two carbonyl groups and a double bond). This imine ring is further connected to a phosphate group via a methylene bridge (-CH₂-). The phosphate group is shown as a phosphorus atom double-bonded to one oxygen and single-bonded to three others, one of which is a hydroxyl group (-OH). The pendant group 'R' is attached to the nitrogen atom of the imine ring.

LE ANWEX 77 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 288629-66-7 CAPLUS
 CN Adenosine 5'-(tetrahydrogen diphosphate), 2' (or 3')-[2-[[6-[2-[2-[1-ethyl-1,3-dihydro-5,2-dimethyl-5-methyl-2H-indol-2-ylidene]-1,2-pentadiene]-5,3-dimethyl-6-methyl-2H-indol-1'-onylhexyl]amino]ethyl]carbamate] (XCI) (CA INDEX NAME)
 CM 1
 CN 288629-66-5
 CIP C26 B16 B4 09 02

PAGE 1-A




PAGE 1-B

-SO₂S

CM 2

CN 18-64-0
 CIP C10 B11 B6 01 09 02

Absolute stereochemistry



IT 162963-66-7P 288628-77-3P 288629-66-6P
 RE BPH (Biological process), REI (Biological study, unclassified); BUI (Biological use, unclassified); CPH (Synthetic preparation); BOM (Biological study), PREP (Preparation), FROC (Process); WBS (Gene) (comparative single-nuc. and ensemble nucleic sequence, using


LE ANWEX 77 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A



RN 288628-77-3 CAPLUS
 CN Adenosine 5'-(tetrahydrogen triphosphate), 2' (or 3')-[2-[[6-[2-[2-[1-ethyl-1,3-dihydro-5,2-dimethyl-5-methyl-2H-indol-2-ylidene]-1,2-pentadiene]-5,3-dimethyl-6-methyl-2H-indol-1'-onylhexyl]amino]ethyl]carbamate] (XCI) (CA INDEX NAME)
 Absolute stereochemistry
 Double bond geometry unknown

PAGE 1-A




PAGE 2-A



RN 288629-66-6 CAPLUS
 CN Adenosine 5'-(tetrahydrogen triphosphate), 2' (or 3')-[2-[[6-[2-[2-[1-ethyl-1,3-dihydro-5,2-dimethyl-5-methyl-2H-indol-2-ylidene]-1,2-pentadiene]-5,3-dimethyl-6-methyl-2H-indol-1'-onylhexyl]amino]ethyl]carbamate] (XCI) (CA INDEX NAME)
 CM 1
 CN 288629-66-5
 CIP C26 B16 B4 09 02


PAGE 1-A



LE ANWEX 77 OF 100 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 288628-67-7 CAPLUS
 CN Adenosine 5'-(tetrahydrogen triphosphate), 2' (or 3')-[2-[[6-[2-[2-[1-ethyl-1,3-dihydro-5,2-dimethyl-5-methyl-2H-indol-2-ylidene]-1,2-pentadiene]-5,3-dimethyl-6-methyl-2H-indol-1'-onylhexyl]amino]ethyl]carbamate], inner salt (CA INDEX NAME)
 Absolute stereochemistry
 Double bond geometry unknown

PAGE 1-A



PAGE 1-B


-SO₂S

L6 ANSWER 82 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
-GTP or 2',5'-diaceto-UTP or -CTP; L = linker attached to 7 position of
purines or 5 position of pyrimidines; when B = deaza-dGTP or deaza-dGTP.

IT 235743-43-8P 235743-44-9F 235743-45-0F
235743-46-1P 235743-47-2P 235743-48-3P
235743-49-4P 235743-50-7F 235743-61-8F
RE: ARG (Analytical reagent use), SPM (Synthetic preparation), ANST
(Analytical study), PREP (Preparation); USBS (Usual)

[illegible]

Absolute stereochemistry
Double bond geometry unknown



PAGE 1-A

16 ANSWER 82 OF 100 CAPLES COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-11



RV 235743-44-9 CAPLUS

CN 3H-Indolium, 2-[6-[1-[6-[3-[4-amino-7-(2R,6S)-tetrahydro-4H-3,5,7,7-tetrahydroxy-3,5,5,7-tetrazolo-2,4,6-triazon-3,5,7,7-triphosphatet-1-yl]-2-furanyl]-2H-pyrido[3,4-b]pyrimidin-6-yl]-2-propen-1-yl]amino]-6-oxobutyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-3-ylidene-L,5-pentadien-1-yl]-ethyl-3,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

Absolute stereochemistry:
Double bond geometry unknown.



PAGE 1-A


L6 ANSWER 82 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



IN 235743-45-0 CAPLUS
 CN 3S-Indolium, 2-[5-{1-[6-[[3-[[2-amino-4,7-dihydro-4-oxo-7-[(2R,5S)-
 tetrahydro-6-[[[hydroxy[[hydroxy(phosphonoethoxy)phosphoryl]oxy]phosphinyl]oxy]
 methyl]-2-furanyl]-3H-pyrrolo[2,3-d,4'-pyrimidin-6-yl]-2-propenyl]-yl]amino-
 6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-
 pentadienyl]-yl]-ethyl]-3,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



PAGE 1-A

L6 ANSWER 82 OF 100 CAPLUS COPYRIGHT 2008 ACS on STN (Cost Issues)


PAGE 1-E




BN 235743-46-1 CAPLUS

CN 1H-Benz[e]indolizium, 2-[5-[3-[6-[[[3-(2-amino-4,7-dihydro-6-oxo-7-[(23,5S)-tetrahydro-6-[[[hydroxy[[hydroxy(phosphonoethoxy)phosphoryl]oxy]phosphoryl]oxy]methoxy]-2-furanyl]-3H-pyrrolo[2,3,3-pyrazin-8-yl]-2-propyl-1-yl]amino]-6-oxohexyl]-1,3-dihydro-1,1-dimethyl-6,8-disulfo-2H-benz[e]indol-2-ylidene)-3-pentadien-1-yl]-3-ethyl-1,1-dimethyl-6,8-disulfo-, inner salt (CA INDEX NAME)

Absolute stereochemistry:
Double bond geometry unknown



PAGE 1-A

L6 ANSWER 88 OF 100 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PAGE 1-11

RE CNT 39 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANCHOR 89 OF CAPLIS COPYRIGHT 2006 ACS on STM
 AN 1268 252658 CAPLIS
 JN 128:290955
 ORIP 128:35485A, 35485B
 TI Fluorescent labeling and electrophoresis of carbohydrates
 TN Jackson, Peter; Cummins, William Jonathan; West, Richard; Smith, John
 Anthony; Briggs, Mark Samuel Jonathan
 PA American International PLC, UK; Jackson, Peter; Cummins, William
 Jonathan; West, Richard; Smith, John Anthony; Briggs, Mark Samuel Jonathan
 A1 PCT Int. Appl., 78 pp
 OOGB: F11010
 DT Patent
 LA English

FIN	INT	ST	KIND	DATE	APPLICATION NO.	DATE
F1	W	0158259	AL	19990616	07/09/082727	19971000 <
	CA	HE	IL	08/01/97		19971000 <
	CA	HE	DE	08/01/97	FR, GB, GR, IE, IT, LU,	19971000 <
	CA	AL	01	19990605	CA 1997-0236237	19971000 <
	EP	0466564	AL	19990605	EP 1997-0466564	19971000 <
	EP	0498176	AL	19990601	EP 1997-0494011	19971000 <
	EP	0498176	AL	19990601		19971000 <
	F	HE, CH, DE, ES, FR, GR, IE, IT, LU, MA, SE	01	20000606		19971000 <
	JP	20001501720	01	20000606	JP 1999-0167396	19971000 <
	SE	200014610	01	20000606	0900011259	19971000 <
	US	0294667	BI	1999000505	US 1999-284046	19990601 <
FRAL	GB	2396-23981	01	19990606		19971000 <
	EP	1997-2055030	AL	19990628		19971000 <


№ 1609-1982 1991/060
The authors have investigated the labeling and separation of fluorescently labeled carbohydrate substances, by virtue of their different charge-to-mass ratios or other factors, so as to enable a much larger number of substances to be separated than can be separated from each other electrophoretically than has been possible previously and to facilitate the study of structural changes and their identification. The authors have also investigated the separation of fluorescent substances. Preferably the method for separating and distinguishing fluorescent substances is applied to fluorescent carbohydrate substances with a fluorescent labeling agent consisting of a fluorescent dye, which is covalently bound to the fluorescent structure, having as a substituent a reactive group capable of reacting with a reducing agent to bind thereto, also having at least one substituent that may be a substituent of the fluorescent structure, and at least one pos. charge which may exist on the fluorescently labeled carbohydrate substances and does not extinguish the fluorescence of the fluorescent reagent. This is useful for separating and distinguishing fluorescent substances to an electrophoretic gel, or other matrix used to support electrophoresis, and may be used to separate and distinguish fluorescent substances of different differentiation of different substances. Preferably the

fluorescent labeling reagent is a cyanine dye
 206814-84-2P 206814-98-6P 206815-02-7P
 206815-06-1P
 RL: ARJ (Analytical reagent use), ARJ (Analytical role, unclassified), EUJ
 (Biological use, unclassified), SPN (Synthetic preparation), ANST
 (Analytical study), BIOL (Biological study), PREP (Preparation), USES
 (Uses)

(fluorescent labeling and electrophoresis of carbohydrates)

266814-84-2 CAPLIS
2H-Indolium, 2-[3-[1-[5-[3-[3-(3-aminopropyl)dimethylammonio]propyl]amino]-3-oxopropyl]-1,3-dihydro-3,5-dimethyl-2H-indol-2-ylidene]-1-propen-1-yl]-1-ethyl-3,3-dimethyl- (CA INDEX NAME)


L6 ANSWER 89 OF 100 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



```

IN  006814-98-8  CAPLUS
CN  SS-Indolizine, 1-[3-[[3-[[3-(8-aminotetrazolyl)dimethylammonio]propyl]dimethylammonio]propyl]amino]-3-oxopropyl]-3-[3-(1-ethyl-1,3-dihydro-3,3-dimethyl-2H-indol-2-ylidene)-1-propenyl]-5,5,3-dimethyl-  CA INDEX NAME

```



PAGE 1-A

PMB 1-B




```

PN 204815-00-7 CAPLUS
CN SS-Indolium, 2-[3-(-[3-(-[3-(-[3-(-[3-amino-propyl)-dimethylammonio]phenyl)-
dimethylammonio]propyl)-dimethylammonio]propyl)amino)-3-oxo-propyl]-1,3-
dihydro-3,3-dimethyl-1H-indol-2-yl; dene]-1-propen-1-yl]-1-ethyl-8,3-
dimethyl-1- (CA INDEX NAME)

```


PAGE 1-A



16 ANSWER 89 OF 100 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



206815-06-1 CAFLUS
 3H-Indolizin-2-[3-1-[3-[3-[3-[4-[3-[3-(3-aminoacetyl)dimethylammonio]oxy]dimethylammonio]phenyl]dimethylammonio]propyl]dimethylammonio]propyl-
 amino]-3-oxopropyl]-1,8-dihydro-3,3-dimethyl-2H-indol-2-ylidene]-1-propen-
 1-yl]-1-methyl-2,3-dimethyl-1H-1H-INDOLIN-3A (INDOLIN NAME)



PAGE 1-A

PAGE 1-8




RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
AN 1996-118140 CAPLUS
IN 151-35699
ORIP 124-47149A, 47152A
TI Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CASO)
AU Chen, Jody; Bellows, Robin; Chen, Zhengrong; Giuliano, Kenneth A.; Schindl, Brigitte F.
CI Center for Light Microscopy Imaging and Biotechnology, Carnegie Mellon University, Pittsburgh, PA 15213, USA
DO Chemistry 1996, 25(1), 49-53
OSON CYCOPOL 133N 0/56-4103
PB Wiley-Liss
PJ Journal
LA English

Progress has been made in improving the immunohistochemical detection of antigens for imaging and flow cytometry. We report the synthesis of a novel fluorescent boronate-hexanediol substrate, Cy5-2P-teramide, and its application in an enzyme-based signal amplification system, catalyzed reporter deposition (CARD). The catalyzed deposition of Cy5-2P-teramide was used to detect cell surface markers such as CD4 and CD85 on tumor tissue and human lymphocytes. We compared the fluorescence CARD method to standard indirect immunofluorescence detection methods and found that an amplification of up to 10-fold was possible with CARD. The detection of the intracellular protein p53 in fibroblastic cells and rabbit serum albumin buried into streptavidin was also improved. Thus, fluorescent CARD is a simple modification that can be made to standard immunofluorescence staining protocols to enhance significantly the detection of antigens.

IT 114961-15-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CASO)
AN 114961-15-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English




IT 114961-16-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CASO)
AN 114961-16-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

A synthetic scheme has been developed for the preparation of a chlorinated analog of polychlorinated biphenyls. The reaction of 2,3,6-trichlorobiphenyl with 3-bromoisobutyrate in the presence of base conditions was used to introduce a free primary amino group into the parent compound by substitution of a stable ether linkage. Reaction of this amine with the succinimide ester of a sulfonodanone dye resulted in a double bond formation to produce a fluorescently-labeled product. The dye conjugate was used to charge a column containing immobilized antibodies against polychlorinated biphenyls. Upon application of samples containing various congeners of polychlorinated biphenyls, the fluorescent analog was displaced from the column in order, proportional to the concentration of analyte. Congeners of polychlorinated biphenyls as low as 1 ppm were measurable using this system.


IT 126792-40-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Analytical study; PREP (Preparation); USS (Use)
AN 126792-40-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

A synthetic scheme has been developed for the preparation of a chlorinated analog of polychlorinated biphenyls. The reaction of 2,3,6-trichlorobiphenyl with 3-bromoisobutyrate in the presence of base conditions was used to introduce a free primary amino group into the parent compound by substitution of a stable ether linkage. Reaction of this amine with the succinimide ester of a sulfonodanone dye resulted in a double bond formation to produce a fluorescently-labeled product. The dye conjugate was used to charge a column containing immobilized antibodies against polychlorinated biphenyls. Upon application of samples containing various congeners of polychlorinated biphenyls, the fluorescent analog was displaced from the column in order, proportional to the concentration of analyte. Congeners of polychlorinated biphenyls as low as 1 ppm were measurable using this system.

IT 126792-40-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Analytical study; PREP (Preparation); USS (Use)
AN 126792-40-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English



LE ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN (Continued)



IT 114961-15-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CASO)
AN 114961-15-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

Progress has been made in improving the immunohistochemical detection of antigens for imaging and flow cytometry. We report the synthesis of a novel fluorescent boronate-hexanediol substrate, Cy5-2P-teramide, and its application in an enzyme-based signal amplification system, catalyzed reporter deposition (CARD). The catalyzed deposition of Cy5-2P-teramide was used to detect cell surface markers such as CD4 and CD85 on tumor tissue and human lymphocytes. We compared the fluorescence CARD method to standard indirect immunofluorescence detection methods and found that an amplification of up to 10-fold was possible with CARD. The detection of the intracellular protein p53 in fibroblastic cells and rabbit serum albumin buried into streptavidin was also improved. Thus, fluorescent CARD is a simple modification that can be made to standard immunofluorescence staining protocols to enhance significantly the detection of antigens.

IT 114961-16-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CASO)
AN 114961-16-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

A synthetic scheme has been developed for the preparation of a chlorinated analog of polychlorinated biphenyls. The reaction of 2,3,6-trichlorobiphenyl with 3-bromoisobutyrate in the presence of base conditions was used to introduce a free primary amino group into the parent compound by substitution of a stable ether linkage. Reaction of this amine with the succinimide ester of a sulfonodanone dye resulted in a double bond formation to produce a fluorescently-labeled product. The dye conjugate was used to charge a column containing immobilized antibodies against polychlorinated biphenyls. Upon application of samples containing various congeners of polychlorinated biphenyls, the fluorescent analog was displaced from the column in order, proportional to the concentration of analyte. Congeners of polychlorinated biphenyls as low as 1 ppm were measurable using this system.

IT 126792-40-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Analytical study; PREP (Preparation); USS (Use)
AN 126792-40-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

A synthetic scheme has been developed for the preparation of a chlorinated analog of polychlorinated biphenyls. The reaction of 2,3,6-trichlorobiphenyl with 3-bromoisobutyrate in the presence of base conditions was used to introduce a free primary amino group into the parent compound by substitution of a stable ether linkage. Reaction of this amine with the succinimide ester of a sulfonodanone dye resulted in a double bond formation to produce a fluorescently-labeled product. The dye conjugate was used to charge a column containing immobilized antibodies against polychlorinated biphenyls. Upon application of samples containing various congeners of polychlorinated biphenyls, the fluorescent analog was displaced from the column in order, proportional to the concentration of analyte. Congeners of polychlorinated biphenyls as low as 1 ppm were measurable using this system.


IT 126792-40-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Analytical study; PREP (Preparation); USS (Use)
AN 126792-40-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English

A synthetic scheme has been developed for the preparation of a chlorinated analog of polychlorinated biphenyls. The reaction of 2,3,6-trichlorobiphenyl with 3-bromoisobutyrate in the presence of base conditions was used to introduce a free primary amino group into the parent compound by substitution of a stable ether linkage. Reaction of this amine with the succinimide ester of a sulfonodanone dye resulted in a double bond formation to produce a fluorescently-labeled product. The dye conjugate was used to charge a column containing immobilized antibodies against polychlorinated biphenyls. Upon application of samples containing various congeners of polychlorinated biphenyls, the fluorescent analog was displaced from the column in order, proportional to the concentration of analyte. Congeners of polychlorinated biphenyls as low as 1 ppm were measurable using this system.

IT 126792-40-0
R: RCT (Reagent), RACT (Reagent or reagent)
AU Analytical study; PREP (Preparation); USS (Use)
AN 126792-40-0 CAPLUS
ORIP 124-47149A, 47152A
TI Synthesis of a Fluorescent Analog of Polychlorinated Biphenyls for Use in a Continuous Flow Immunosensor Array
AU Charles, Paul T.; Conrad, David P.; Jacobs, Megan S.; Bart, John C.; Bartelme, Jere H.
CI Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5040, USA
DO Immunology Chemistry 1995, 6(6), 691-4
OSON ANDER SE OF 100 CAPLUS CRYPTICOT 2008 ACS on STN
PB American Chemical Society
PJ Journal
LA English



Absolute stereochemistry. Double bond geometry unknown.




```

=> => d que 113 stat
L7      34 SEA FILE=CAPLUS ABB=ON PLU=ON "WILLIAMS KAREN"/AU
L8      15 SEA FILE=CAPLUS ABB=ON PLU=ON ("STONE TIM"/AU OR "STONE
        TIMOTHY"/AU OR "STONE TIMOTHY J"/AU)
L9      18 SEA FILE=CAPLUS ABB=ON PLU=ON ("SIMMONDS ADRIAN"/AU OR
        "SIMMONDS ADRIAN C"/AU OR "SIMMONDS ADRIAN CHRISTOPHER"/AU)
L10     5 SEA FILE=CAPLUS ABB=ON PLU=ON ("SWEET ALISON"/AU OR "SWEET
        ALISON CLAIRE"/AU)
L11     20 SEA FILE=CAPLUS ABB=ON PLU=ON "FOWLER SUSAN"/AU OR "FOWLER
        SUSAN J"/AU OR "FOWLER SUSAN JANET"/AU
L12     84 SEA FILE=CAPLUS ABB=ON PLU=ON L7 OR L8 OR L9 OR L10 OR L11
L13     10 SEA FILE=CAPLUS ABB=ON PLU=ON L12 AND DYE

```

```

=> d 1-10 bib abs

```


L13 NUMBER 6 OF 10 CAPSULE OFFPRINTS 2000 ACS ON STN
AN 2000-12143 CAPSULE
IN 137-121946
TI Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of *Escherichia coli*
AU Yan, Jun X.; Deveshwar, Angelina T.; Watt, Robin; Stone, Tim;
CO American Bioresources, Little Chalfont, UK
SO Proteomics 2000; 2(12): 1603-1609
OR PNAS 199707; 94(28): 16155-16162
PT Journal
LA English
AB Separation and relative quantitation of complex protein mixtures remains one of the most challenging aspects of proteomics. Here an advanced technique called fluorescence difference 2-D gel electrophoresis (method, CIP-2010) has been applied to a model system study of the *Escherichia coli* proteome after serine and treatment. The mol. weight and charge matched protein spots enable pre-electrophoretic labeling of control and treated samples within one 2-D gel and run in the same gel. Pooled control and treated samples labeled with Cy5 were used as an internal standard for both 2-D labeled control and treated 2-D gels. Together with 2-D laser imaging and, software, more accurate quant. anal. than conventional two-dimensional PAGE was achieved. Using matrix-assisted laser desorption/ionization-time of flight and quadrupole-time of flight mass spectrometry a total of 170 differentially expressed protein spots were identified. These included enzymes, stress related and substrate G protein, acidic, alkaline, and TSP (transposon) binding proteins. Of the spots analyzed, 170 contained only one protein species per spot, hence the change in protein expression measured was solely attributed to the identified protein. Many membrane proteins and protein isoforms were identified indicating both adaptive inhibition of E. coli samples and potential post-translational modification. The results indicate that the regulatory mechanisms following serine and treatment of E. coli are far more complicated than hitherto expected.

RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THIS RECORD

L13 NUMBER 6 OF 10 CAPSULE OFFPRINTS 2000 ACS ON STN (Continued)
AN 2000-12143 CAPSULE
IN 137-121946
TI Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of *Escherichia coli*
AU Yan, Jun X.; Deveshwar, Angelina T.; Watt, Robin; Stone, Tim;
CO American Bioresources, Little Chalfont, UK
SO Proteomics 2000; 2(12): 1603-1609
OR PNAS 199707; 94(28): 16155-16162
PT Journal
LA English
AB Separation and relative quantitation of complex protein mixtures remains one of the most challenging aspects of proteomics. Here an advanced technique called fluorescence difference 2-D gel electrophoresis (method, CIP-2010) has been applied to a model system study of the *Escherichia coli* proteome after serine and treatment. The mol. weight and charge matched protein spots enable pre-electrophoretic labeling of control and treated samples within one 2-D gel and run in the same gel. Pooled control and treated samples labeled with Cy5 were used as an internal standard for both 2-D labeled control and treated 2-D gels. Together with 2-D laser imaging and, software, more accurate quant. anal. than conventional two-dimensional PAGE was achieved. Using matrix-assisted laser desorption/ionization-time of flight and quadrupole-time of flight mass spectrometry a total of 170 differentially expressed protein spots were identified. These included enzymes, stress related and substrate G protein, acidic, alkaline, and TSP (transposon) binding proteins. Of the spots analyzed, 170 contained only one protein species per spot, hence the change in protein expression measured was solely attributed to the identified protein. Many membrane proteins and protein isoforms were identified indicating both adaptive inhibition of E. coli samples and potential post-translational modification. The results indicate that the regulatory mechanisms following serine and treatment of E. coli are far more complicated than hitherto expected.

RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THIS RECORD

L13 NUMBER 6 OF 10 CAPSULE OFFPRINTS 2000 ACS ON STN
AN 2000-12143 CAPSULE
IN 137-121946
TI Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of *Escherichia coli*
AU Yan, Jun X.; Deveshwar, Angelina T.; Watt, Robin; Stone, Tim;
CO American Bioresources, Little Chalfont, UK
SO Proteomics 2000; 2(12): 1603-1609
OR PNAS 199707; 94(28): 16155-16162
PT Journal
LA English
AB Separation and relative quantitation of complex protein mixtures remains one of the most challenging aspects of proteomics. Here an advanced technique called fluorescence difference 2-D gel electrophoresis (method, CIP-2010) has been applied to a model system study of the *Escherichia coli* proteome after serine and treatment. The mol. weight and charge matched protein spots enable pre-electrophoretic labeling of control and treated samples within one 2-D gel and run in the same gel. Pooled control and treated samples labeled with Cy5 were used as an internal standard for both 2-D labeled control and treated 2-D gels. Together with 2-D laser imaging and, software, more accurate quant. anal. than conventional two-dimensional PAGE was achieved. Using matrix-assisted laser desorption/ionization-time of flight and quadrupole-time of flight mass spectrometry a total of 170 differentially expressed protein spots were identified. These included enzymes, stress related and substrate G protein, acidic, alkaline, and TSP (transposon) binding proteins. Of the spots analyzed, 170 contained only one protein species per spot, hence the change in protein expression measured was solely attributed to the identified protein. Many membrane proteins and protein isoforms were identified indicating both adaptive inhibition of E. coli samples and potential post-translational modification. The results indicate that the regulatory mechanisms following serine and treatment of E. coli are far more complicated than hitherto expected.

RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THIS RECORD

L13 NUMBER 6 OF 10 CAPSULE OFFPRINTS 2000 ACS ON STN
AN 2000-12143 CAPSULE
IN 137-121946
TI Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of *Escherichia coli*
AU Yan, Jun X.; Deveshwar, Angelina T.; Watt, Robin; Stone, Tim;
CO American Bioresources, Little Chalfont, UK
SO Proteomics 2000; 2(12): 1603-1609
OR PNAS 199707; 94(28): 16155-16162
PT Journal
LA English
AB Separation and relative quantitation of complex protein mixtures remains one of the most challenging aspects of proteomics. Here an advanced technique called fluorescence difference 2-D gel electrophoresis (method, CIP-2010) has been applied to a model system study of the *Escherichia coli* proteome after serine and treatment. The mol. weight and charge matched protein spots enable pre-electrophoretic labeling of control and treated samples within one 2-D gel and run in the same gel. Pooled control and treated samples labeled with Cy5 were used as an internal standard for both 2-D labeled control and treated 2-D gels. Together with 2-D laser imaging and, software, more accurate quant. anal. than conventional two-dimensional PAGE was achieved. Using matrix-assisted laser desorption/ionization-time of flight and quadrupole-time of flight mass spectrometry a total of 170 differentially expressed protein spots were identified. These included enzymes, stress related and substrate G protein, acidic, alkaline, and TSP (transposon) binding proteins. Of the spots analyzed, 170 contained only one protein species per spot, hence the change in protein expression measured was solely attributed to the identified protein. Many membrane proteins and protein isoforms were identified indicating both adaptive inhibition of E. coli samples and potential post-translational modification. The results indicate that the regulatory mechanisms following serine and treatment of E. coli are far more complicated than hitherto expected.

RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THIS RECORD

L13 NUMBER 6 OF 10 CAPSULE OFFPRINTS 2000 ACS ON STN
AN 2000-12143 CAPSULE
IN 137-121946
TI Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of *Escherichia coli*
AU Yan, Jun X.; Deveshwar, Angelina T.; Watt, Robin; Stone, Tim;
CO American Bioresources, Little Chalfont, UK
SO Proteomics 2000; 2(12): 1603-1609
OR PNAS 199707; 94(28): 16155-16162
PT Journal
LA English
AB Separation and relative quantitation of complex protein mixtures remains one of the most challenging aspects of proteomics. Here an advanced technique called fluorescence difference 2-D gel electrophoresis (method, CIP-2010) has been applied to a model system study of the *Escherichia coli* proteome after serine and treatment. The mol. weight and charge matched protein spots enable pre-electrophoretic labeling of control and treated samples within one 2-D gel and run in the same gel. Pooled control and treated samples labeled with Cy5 were used as an internal standard for both 2-D labeled control and treated 2-D gels. Together with 2-D laser imaging and, software, more accurate quant. anal. than conventional two-dimensional PAGE was achieved. Using matrix-assisted laser desorption/ionization-time of flight and quadrupole-time of flight mass spectrometry a total of 170 differentially expressed protein spots were identified. These included enzymes, stress related and substrate G protein, acidic, alkaline, and TSP (transposon) binding proteins. Of the spots analyzed, 170 contained only one protein species per spot, hence the change in protein expression measured was solely attributed to the identified protein. Many membrane proteins and protein isoforms were identified indicating both adaptive inhibition of E. coli samples and potential post-translational modification. The results indicate that the regulatory mechanisms following serine and treatment of E. coli are far more complicated than hitherto expected.

RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THIS RECORD

=> d his full

(FILE 'HOME' ENTERED AT 13:38:29 ON 07 JUL 2008)

FILE 'REGISTRY' ENTERED AT 13:38:47 ON 07 JUL 2008

L1 STRUCTURE UPLOADED
 D
 L2 26 SEA SSS SAM L1
 L3 515 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 13:41:00 ON 07 JUL 2008

L4 231 SEA ABB=ON PLU=ON L3
 L5 55 SEA ABB=ON PLU=ON L4 AND PY<2003
 D QUE L5 STAT
 D 1-55 BIB ABS HITSTR
 L6 100 SEA ABB=ON PLU=ON L4 AND PY<2005
 D 1-100 BIB ABS HITSTR
 E WILLIAMS KAREN/AU
 L7 34 SEA ABB=ON PLU=ON "WILLIAMS KAREN"/AU
 E STONE TIMOTHY/AU
 L8 15 SEA ABB=ON PLU=ON ("STONE TIM"/AU OR "STONE TIMOTHY"/AU OR
 "STONE TIMOTHY J"/AU)
 E SIMMONDS ADRIAN/AU
 L9 18 SEA ABB=ON PLU=ON ("SIMMONDS ADRIAN"/AU OR "SIMMONDS ADRIAN
 C"/AU OR "SIMMONDS ADRIAN CHRISTOPHER"/AU)
 E SWEET ALISON/AU
 L10 5 SEA ABB=ON PLU=ON ("SWEET ALISON"/AU OR "SWEET ALISON
 CLAIRE"/AU)
 E FOWLER SUSAN/AU
 L11 20 SEA ABB=ON PLU=ON "FOWLER SUSAN"/AU OR "FOWLER SUSAN I"/AU

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2008 VOL 149 ISS 2
 FILE LAST UPDATED: 6 Jul 2008 (20080706/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION


FULL ESTIMATED COST

912.85	1092.80
--------	---------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> log h

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

0.46 1093.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

0.00 -132.00